Introduction {#s1}
============

Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease and the leading genetic cause of infant death in the US ([@bib12]; [@bib68]). SMA is caused by homozygous deletion or mutation of the *SMN1 (Survival Motor Neuron 1)* gene, resulting in reduced Survival of Motor Neuron (SMN) protein levels ([@bib50]). SMN expression is ubiquitous, but particularly essential for motor neuron survival ([@bib51]). Disease severity, as well as spinal cord α-MN dysfunction and degeneration, correlates with the extent of SMN loss ([@bib51]). Understanding why SMN loss impairs function should offer insight into SMA and may reveal therapeutic targets. SMN is conserved across species ([@bib60]). Studies of various SMA models suggest a role for SMN in several cellular processes including snRNP assembly ([@bib30]; [@bib96]), messenger RNA (mRNA) transport ([@bib23]), and local translation ([@bib15]; [@bib48]). SMN function, however, has not been linked definitively to MN degeneration or synaptic transmission defects caused by SMN loss.

microRNAs (miRNAs) are non-coding RNAs that often repress protein translation, by a mechanism that requires miRNA binding to the 3'UTR of mRNA targets. Disruption of the miRNA pathway in spinal MNs leads to severe degeneration ([@bib33]). SMN loss alters levels and/or activity of specific miRNAs ([@bib33]; [@bib48]; [@bib86]; [@bib89]), but the cellular mechanisms leading to altered miRNA expression and/or function are unknown. The RNA helicase Gemin3 associates with both SMN and RNA-induced silencing complex components ([@bib8]; [@bib38]; [@bib37]; [@bib59]; [@bib62]; [@bib63]). Gemin3 and SMN levels decrease concomitantly, suggestive of a functional link ([@bib24]; [@bib34]).

We took advantage of the *C. elegans* SMA model to examine the connection between SMN, Gemin3, and miRNA function. *SMN1*, *Gemin3,* and multiple miRNA pathway components are conserved in *C. elegans* ([@bib32]; [@bib60]; [@bib61]). Loss-of-function (lf) mutations in *smn-1*, the *C. elegans* ortholog of *SMN1*, cause behavioral and morphological abnormalities, premature death, and sterility ([@bib4]; [@bib78]). *smn-1(lf)* animals also have neuromuscular junction (NMJ) defects, suggesting a functional role for SMN-1 in MNs ([@bib4]). MNs in *smn-1(lf)* animals do not die, likely because of their short lifespan. However, *smn-1(lf)* neuromuscular defects may correspond to the early stages of SMA pathogenesis, characterized by NMJ dysfunction prior to MN degeneration ([@bib60]; [@bib97]). We find that the *C. elegans* Gemin3 ortholog, MEL-46, is perturbed by SMN-1 loss, impacting miR-2 suppression of the M2 muscarinic receptor ortholog, GAR-2 ([@bib49]). Across species in SMA mouse models, we find decreased levels of miR-128, a potential miR-2 ortholog, and increased expression of the GAR-2 ortholog, m2R. Notably, m2R inhibition ameliorates axon outgrowth defects in MNs from a SMA mouse model, consistent with our results in *C. elegans*.

Results {#s2}
=======

MEL-46 (Gemin3) is required for NMJ function {#s2-1}
--------------------------------------------

The *C. elegans* Gemin3 ortholog is MEL-46. Homozygous loss of *smn-1* or *mel-46* results in lethality ([@bib4]; [@bib60]), but maternal loading of *smn-1* or *mel-46* mRNA and protein allows many homozygous, loss of function animals to survive into the last larval stage, called L4 ([@bib60]; [@bib61]). Loss of *smn-1* results in neuromuscular defects including decreased pharyngeal pumping rates, followed by overtly altered locomotion and subsequent death ([@bib4]). Like *smn-1* loss in L4 stage animals, we found that *mel-46(tm1739)* homozygous loss of function animals had severely decreased pharyngeal pumping rates. Pharyngeal pumping was restored to normal rates in *mel-46(tm1739)* animals using a previously described, broadly expressed *mel-46* rescue array (also referred to as \[*mel-46(+)*\#1\]), which utilizes the *mel-46* promoter ([Figure 1A](#fig1){ref-type="fig"}) ([@bib61]). *mel-46* partial loss of function alleles, *yt5* and *ok3760*, also caused pumping defects as did global *mel-46* RNA interference (*RNAi*) or cholinergic neuron-specific *mel-46(RNAi)* ([Figure 1---figure supplement 1A--E](#fig1s1){ref-type="fig"}). We conclude that MEL-46 is necessary for normal neuromuscular function.10.7554/eLife.20752.003Figure 1.Decreased MEL-46 function in *C. elegans* results in defective NMJ signaling.(**a**) *mel-46(tm1739)* animals had reduced pharyngeal pumping rates *versus* wild type (N2) control animals. Defects were fully rescued by global expression of MEL-46 behind its own promoter (\[*mel-46(+)\#1*\]). Mean ± SEM; Mann-Whitney *U*-test, two-tailed. (**b**) *mel-46(tm1739)* animals paralyzed more slowly when exposed to aldicarb, an acetylcholinesterase inhibitor. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mel-46(tm1739),* and *mel-46(tm1739);\[mel-46(+)\#1*\] early larval stage L4 animals. Reintroduction of *mel-46* restored normal aldicarb sensitivity. Log-rank test. (**c**) Cholinergic neuron-specific *mel-46(RNAi)* causes resistance to aldicarb. Time course for paralysis on 1.5 mM aldicarb for empty(*RNAi*), *smn-1(RNAi)*, *mel-46(RNAi)*, and *goa-1(RNAi)* young adult animals. Animals sensitive to RNAi in only cholinergic neurons (XE1581) were fed bacteria expressing double-stranded RNA (dsRNA) against *mel-46*, *smn-1,* or *goa-1* (positive control). Control animals were fed bacteria expressing an empty vector control: empty(*RNAi*). Data set previously published without *mel-46(RNAi)* ([@bib17]). Log-rank test. (**d**) *mel-46(tm1739)* animals had reduced RFP::SNB-1 (synaptobrevin). Percent change from wild type (N2) control for RFP::SNB-1 in the dorsal cord of *mel-46(tm1739)* and *mel-46(tm1739);*\[*mel-46(+)\#1*\] animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to wild type; shading indicates significant change for *mel-46(tm1739) versus mel-46(tm1739);*\[*mel-46(+)\#1*\]. Mann-Whitney *U*-test, two-tailed. Expression of *mel-46* rescued RFP::SNB-1 puncta width defects in *mel-46(tm1739)* animals (wild type *versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.82); *mel-46(tm1739) versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.03), rescued SNB-1 puncta intensity defects (wild type *versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.85; *mel-46(tm1739) versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.005) and partially ameliorated SNB-1 puncta linear density defects (wild type *versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.0004); *mel-46(tm1739) versus mel-46(tm1739);*\[*mel-46(+)\#1*\] *p=*0.0001). (**h--j**) Representative images of RFP::SNB-1 expressed in the dorsal cord of cholinergic DA MNs for wild type, *mel-46(tm1739),* and *mel-46(tm1739);*\[*mel-46(+)\#1*\] animals. These images were taken as part of data collection. Scale bar, 5 μm. For statistical analyses in all figures: \**p*≤0.05, \*\**p*\<0.01, \*\*\**p*\<0.001. A helpful summary of *C. elegans* phenotypes reported throughout this article for selected loss of function alleles can be found in [Supplementary file 1](#SD16-data){ref-type="supplementary-material"}. Additional information on *C. elegans* strains used in [Figures 1](#fig1){ref-type="fig"}--[6](#fig6){ref-type="fig"} is provided in [Supplementary file 2A](#SD17-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.003](10.7554/eLife.20752.003)10.7554/eLife.20752.004Figure 1---source data 1.Raw Data for [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.004](10.7554/eLife.20752.004)10.7554/eLife.20752.005Figure 1---figure supplement 1.MEL-46(Gemin3) is necessary for proper NMJ function.(**a**) Schematic representation of the predicted *mel-46* gene. Large arrow indicates the direction of translation. Also shown are the positions of the *yt5* G to A transition, the *tm1739* deletion and the *ok3760* complex substitution, for which the inserted sequence is indicated ([@bib61]). (**b**) *mel-46(yt5)* animals had reduced pharyngeal pumping rates *versus* wild type (N2) control. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**c**) *mel-46(ok3760)* animals had reduced pharyngeal pumping rates *versus* wild type (N2) control. Mean ± SEM; *t*-test, two tailed. This data was collected alongside data in [Figure 1A](#fig1){ref-type="fig"}. (**d**) Animals sensitive to RNAi in all tissues (KP3948) fed bacteria expressing double-stranded RNA (dsRNA) against *mel-46* had reduced pharyngeal pumping rates *versus* control animals fed bacteria expressing an empty vector control. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**e**) Animals sensitive to RNAi in only cholinergic neurons (XE1581) fed bacteria expressing double-stranded RNA (dsRNA) against *mel-46* had reduced pharyngeal pumping rates *versus* control animals fed bacteria expressing an empty vector control. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**f**) *mel-46(yt5)* animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Broad expression of MEL-46 with \[*mel-46(+)\#3*\], which uses the *mel-46* promoter, did not significantly restore *mel-46(yt5)* aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mel-46(yt5),* and *mel-46(yt5);\[mel-46(+)\#3\]* early larval stage L4 animals. Log-rank test. (**g**) *mel-46(ok3760)* animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2) and *mel-46(ok3760)* young adult animals. Log-rank test. This data was collected alongside data in [Figure 1B](#fig1){ref-type="fig"}. (**h**) GABA neuron-specific *mel-46* RNAi or *smn-1* RNAi results in aldicarb hypersensitivity. Time course for paralysis on 1 mM aldicarb for empty(*RNAi*), *smn-1(RNAi)*, *mel-46(RNAi)*, and *unc-25(RNAi)* animals. Animals sensitive to RNAi in only GABAergic neurons (XE1375) were fed bacteria expressing double-stranded RNA (dsRNA) against *mel-46, smn-1,* or *unc-25* (positive control). Control animals were fed bacteria expressing an empty vector control: empty(*RNAi*). Log-rank test. For all statistical analyses in figure supplements: \**p*≤0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.005](10.7554/eLife.20752.005)10.7554/eLife.20752.006Figure 1---figure supplement 1---source data 1.Raw Data for [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.Raw data and statistical analysis that correspond to pumping and aldicarb resistance assays in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.006](10.7554/eLife.20752.006)10.7554/eLife.20752.007Figure 1---figure supplement 2.MEL-46(Gemin3) loss causes increased APT-4(AP2 α-adaptin) linear density.(**a**) *mel-46(tm1739)* animals had increased APT-4 (AP2 α-adaptin) linear density. Percent change from wild type control for APT-4 in the dorsal nerve cord of *mel-46(tm1739)* animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Mann-Whitney *U*-test, two-tailed. (**b--c**) Representative images of APT-4::GFP in the dorsal nerve cord of cholinergic DA MNs of wild type and *mel-46(tm1739)* animals. These images were taken as part of data collection. Scale bar, 5 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.007](10.7554/eLife.20752.007)10.7554/eLife.20752.008Figure 1---figure supplement 2---source data 1.Raw Data for [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.008](10.7554/eLife.20752.008)

SMN-1 is required for normal NMJ function in *C. elegans* cholinergic MNs ([@bib17]). Aldicarb is an acetylcholinesterase inhibitor that leads to acetylcholine accumulation in the NMJ and consequently, paralysis ([@bib54]). The time course of aldicarb-induced paralysis was slowed by decreased SMN-1 activity ([@bib17]). We tested if a decrease in MEL-46 function causes similar resistance to aldicarb and found that *mel-46* loss of function resulted in aldicarb resistance across multiple alleles ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1F and G](#fig1s1){ref-type="fig"}), reminiscent of *smn-1* loss. Reintroduction of *mel-46* using the \[*mel-46(+)*\#1\] rescue array restored aldicarb sensitivity in *mel-46(tm1739)* animals. Tissue-specific knock-down of *mel-46* in cholinergic neurons resulted in aldicarb resistance, thus confirming that MEL-46 function is required in cholinergic neurons, as is SMN-1 ([Figure 1C](#fig1){ref-type="fig"}) ([@bib17]). We also showed that knock-down of *mel-46* or *smn-1* in inhibitory GABAergic neurons resulted in aldicarb hypersensitivity ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}). Our findings, taken together with previous work, suggest that MEL-46 and SMN-1 are required in both cholinergic and GABAergic neurons for normal NMJ function.

*smn-1* loss causes changes in presynaptic protein localization ([@bib17]). Do similar changes occur in *mel-46(tm1739)* animals? We evaluated localization of presynaptic proteins SNB-1 (synaptobrevin) and APT-4 (AP2 α-adaptin) in cholinergic dorsal A-type (DA) MNs of *mel-46(tm1739)* animals ([@bib7]; [@bib76]). SNB-1 is a v-SNARE protein required for SV exocytosis, while APT-4 associates with clathrin-coated endocytic vesicles ([@bib43]; [@bib65]). In the dorsal cord, cholinergic DA MNs do not have presynaptic inputs; they form *en passant* presynaptic connections in a punctate pattern ([@bib7]; [@bib93]). Three parameters were measured to evaluate fluorescently labeled SNB-1 and APT-4 localization to presumptive synapses: puncta width (μm), intensity (AU), and linear density (puncta/μm), as previously described ([@bib45]). Loss of *smn-1* or *mel-46* resulted in similar SNB-1 synaptic localization defects: decreased SNB-1 puncta width, intensity and linear density ([Figure 1D--G](#fig1){ref-type="fig"}) ([@bib17]). Loss of *smn-1* leads to decreased APT-4 puncta width and intensity, but increased linear density ([@bib17]). *mel-46(tm1739)* animals also had increased APT-4 linear density, but no changes in puncta width or intensity compared to controls ([Figure 1---figure supplement 2A--C](#fig1s2){ref-type="fig"}). Therefore, decreased *mel-46* causes synaptic protein defects that overlap partially with defects observed when SMN-1 levels decrease. Given the similarities between SMN-1 and MEL-46 loss in aldicarb resistance, decreased pharyngeal pumping rates, and defective synaptic protein localization, we decided to explore whether SMN-1 and MEL-46 act in common pathways required for NMJ function.

Perturbed MEL-46 (Gemin3) function likely contributes to synaptic defects in *smn-1(lf)* animals {#s2-2}
------------------------------------------------------------------------------------------------

MEL-46 might act together with or downstream of SMN-1 in pathways necessary for NMJ function. To test these and other possibilities, we generated integrated multicopy transgenic lines expressing GFP-tagged MEL-46 expressed under control of the *unc-17* cholinergic-specific promoter ([Figure 2A](#fig2){ref-type="fig"}). MEL-46::GFP was found in both the cell bodies and processes of neurons. No obvious changes were seen in cytoplasmic MEL-46::GFP, leading us to evaluate localization of MEL-46::GFP in MN dorsal cord processes in *smn-1(ok355)* animals. Because *ok355* deletion in *smn-1* leads to a complete loss of function, *smn-1(ok355)* animals were maintained over an *hT2* balancer and sterile *smn-1(ok355)* homozygous progeny carry some maternally-loaded SMN-1 protein ([@bib4]). We found that MEL-46::GFP localizes to small granular structures in dorsal cord processes in control (*smn-1(+)*) and *smn-1(ok355)* animals. Our finding is consistent with previous work showing that Gemin3 localizes to granular structures in mammalian neurites; Gemin3 co-localizes with SMN in 50--60% of these granules, along with multiple mRNAs ([@bib84], [@bib85]; [@bib98]). In *smn-1(ok355)* animals, we found that the density of MEL-46::GFP-positive granular structures was doubled compared to *smn-1(+)* controls ([Figure 2B--D](#fig2){ref-type="fig"}). Furthermore, the mean intensity of MEL-46::GFP fluorescence and the maximum fluorescence for each sample were decreased in *smn-1(ok355)* animals ([Figure 2B--D](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). These results suggest that decreased SMN-1 leads to MEL-46 mislocalization in cholinergic MN processes and diminished MEL-46 levels in granules. Our findings suggest that SMN-1 impairs MEL-46 function, which could contribute to *smn-1(ok355)* synaptic defects ([@bib17]). To test this hypothesis, we increased *mel-46* gene dosage in *smn-1(ok355)* animals using the \[*mel-46(+)\#1*\] rescue array and showed that this ameliorated *smn-1(ok355)* aldicarb resistance defects ([Figure 2E](#fig2){ref-type="fig"}). We also showed that increasing *mel-46* specifically in cholinergic neurons, using the cholinergic-specific *unc-17* (ACh) promoter in an integrated array, referred to as \[ACh::*mel-46*::GFP\], rescued *smn-1(ok355)* aldicarb resistance ([Figure 2---figure supplement 1B and C](#fig2s1){ref-type="fig"}). The aldicarb resistance observed with broad expression of *mel-46* in control animals ([Figure 2E](#fig2){ref-type="fig"}) was not observed when we overexpressed *mel-46* in cholinergic neurons only. Under this condition we observed mild hypersensitivity in one integrated line (referred to as \[ACh::*mel-46::*GFP\#1\]) ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}) and no difference from control animals in a second line (referred to as \[ACh::*mel-46::*GFP\#2\]) ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). It is possible that high levels of MEL-46 in cholinergic neurons cause aldicarb hypersensitivity, whereas broad overexpression of MEL-46 may impact NMJ function independent of cholinergic neurons. Taken together, our results suggest that loss of SMN-1 negatively impacts MEL-46 function, resulting in perturbed NMJ signaling. Our finding is consistent with observations in humans that reduced human SMN levels result in Gemin3 downregulation ([@bib24]; [@bib34]),10.7554/eLife.20752.009Figure 2.MEL-46 localization and levels are perturbed in *smn-1(lf)* animals.(**a**) Illustration: *mel-46* was tagged with GFP at the C-terminus and expression was driven by the cholinergic (ACh) *unc-17* promoter. Two lines were generated by UV integration. (**b**) *smn-1(ok355)* animals exhibited mislocalization and reduction of MEL-46::GFP in dorsal cord processes of cholinergic neurons. MEL-46::GFP localizes to granular punctate structures in dorsal cord processes. Percent change from *smn-1(+)* control for MEL-46::GFP in the dorsal cord of *smn-1(ok355)* animals for ImageJ parameters: puncta density (puncta/area), puncta intensity (AU), and puncta size (pixels/puncta). The ImageJ analysis was used instead of the 'punctaanalyzer' program since MEL-46::GFP had a scattered non-linear pattern in *smn-1(ok355)* animals; a linear pattern is necessary for accurate 'punctaanalyzer' analysis. Asterisks denote significance compared to wild type. Mann-Whitney *U*-test, two-tailed. (**c--d**) Representative images of MEL-46::GFP in dorsal cord cholinergic DA MN processes for control *smn-1*(*+*) and *smn-1*(*ok355*) animals. These images were taken as part of data collection. Scale bar, 5 μm. (**e**) Increasing expression of *mel-46* rescued *smn-1(ok355)* aldicarb response defects. Time course for paralysis on 1 mM aldicarb for *smn-1(+)*, *smn-1(ok355), smn-1(ok355);*\[*mel-46(+)\#1*\], and *smn-1(+)*;\[*mel-46(+)\#1*\] early larval stage L4 animals. *smn-1(+);*\[*mel-46(+)\#1*\] animals were resistant to paralysis by aldicarb. Log-rank test. (**f**) Increasing *mel-46* rescued *smn-1(ok355)* RFP::SNB-1 synaptic localization defects. Percent change from *smn-1(+)* control for RFP::SNB-1 in the dorsal cord of *smn-1(ok355), smn-1(ok355);*\[*mel-46(+)\#1*\], and *smn-1(+);*\[*mel-46(+)\#1*\] animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to *smn-1(+)* control; shading indicates significant difference from *smn-1(ok355);\[mel-46(+)\#1\].* Mann-Whitney *U*-test, two-tailed. Expression of *mel-46* restored RFP::SNB-1 puncta width defects (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.05; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.001), rescued SNB-1 puncta intensity defects (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.035; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.0004), but did not rescue SNB-1 puncta linear density defects (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.036; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#1*\] *p=*0.19). (**G--J**) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal nerve cord of *smn-1(+), smn-1(ok355)* and *smn-1(ok355);*\[*mel-46(+)\#1*\]. These images were taken as part of data collection. Scale bar, 5 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.009](10.7554/eLife.20752.009)10.7554/eLife.20752.010Figure 2---source data 1.Raw Data for [Figure 2](#fig2){ref-type="fig"}.Raw data and statistical analysis that correspond to MEL-46::GFP localization, aldicarb resistance assays, and RFP::SNB-1 localization analysis in [Figure 2](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.010](10.7554/eLife.20752.010)10.7554/eLife.20752.011Figure 2---figure supplement 1.Expressing *mel-46* restores neuronal defects in *smn-1(lf)* animals.(**a**) Decreased SMN-1 resulted in a 21% decrease in maximum MEL-46::GFP fluorescence in dorsal cord DA motor neuron processes. Histogram of maximum fluorescence (AU) for *smn-1(+)* and *smn-1(ok355)* animals. *t*-test. p\<0.01. (**b**) Increasing cholinergic expression using the *unc-17* (ACh) promoter of *mel-46* partially rescued *smn-1(ok355)* aldicarb response defects. Time course for paralysis on 1 mM aldicarb for *smn-1(+)*, *smn-1(ok355), smn-1(ok355);*\[ACh*::mel-46::GFP \#1*\], and *smn-1(+)*;\[ACh*::mel-46::GFP \#1*\] early larval stage L4 animals. Log-rank test. (**c**) Increasing cholinergic expression of *mel-46* resulted in rescue of *smn-1(ok355)* aldicarb response defects. Time course for paralysis on 1 mM aldicarb for *smn-1(+)*, *smn-1(ok355), smn-1(ok355);*\[ACh*::mel-46::GFP \#1*\], and *smn-1(+)*;\[ACh*::mel-46::GFP \#1*\] early larval stage L4 animals. *smn-1(+)*;\[ACh*::mel-46::GFP \#1*\] were hypersensitive to paralysis by aldicarb. Log-rank test. (**c--d**) The same MEL-46::GFP integrated lines were used to evaluate levels and localization in [Figure 2B--D](#fig2){ref-type="fig"}. Despite rescue *smn-1(ok355)* aldicarb resistance, these animals expressing cholinergic MEL-46::GFP still exhibit MEL-46 mislocalization likely leading to decreased function. This rescue may occur because enough MEL-46::GFP is expressed to overcome mislocalization-related functional deficits. (**d**) *smn-1(ok355)* animals had reduced pharyngeal pumping rates *versus smn-1(+)* control animals; defects were not rescued by increasing *mel-46* using the \[*mel-46)+)\#1*\] array. *smn-1(+);* \[*mel-46(+)\#1*\] animals had pharyngeal pumping rates indistinguishable from *smn-1(+)* controls. Mean ± SEM; Mann-Whitney *U*-test, two-tailed. (**e**) Broad expression of MEL-46 using the *mel-46* promoter ameliorated the APT-4 (AP2 α-adaptin) linear density defect in *smn-1(ok355)* animals. Percent change from *smn-1(+)* control for APT-4 in the dorsal cord of *smn-1(ok355)* and *smn-1(ok355);*\[*mel-46(+)\#2*\] animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance *versus smn-1(+)* control; shading indicates *smn-1(ok355)* is significantly different from *smn-1(ok355);*\[*mel-46(+)\#2*\]. Mann-Whitney *U*-test, two-tailed. Expression of MEL-46 did not rescue APT-4 puncta width (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.006; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.48), did not rescue APT-4 total puncta intensity (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.002; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.27), but ameliorated APT-4 puncta linear density (*smn-1(+)* control *versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.93; *smn-1(ok355) versus smn-1(ok355);*\[*mel-46(+)\#2*\] *p=*0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.20752.011](10.7554/eLife.20752.011)10.7554/eLife.20752.012Figure 2---figure Supplement 1---source data 1.Raw Data for [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.Raw data and statistical analysis that correspond to MEL-46::GFP localization, APT-4::GFP localization analysis, aldicarb resistance and pumping assays in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.012](10.7554/eLife.20752.012)10.7554/eLife.20752.013Figure 2---figure supplement 2.Expressing *mel-46* does not increase SMN-1 levels.(**a**) Illustration: *smn-1(rt280)* was generated by CRISPR-mediated insertion of GFP upstream of *smn-1* exon 1. (**b**) Increasing MEL-46 expression using the \[*mel-46(+)\#2*\] array led to decreased GFP::SMN-1 fluorescence. Quantification of mean *smn-1(rt280)* GFP fluorescence in wild type and \[*mel-46(+)\#2*\] backgrounds. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**c**) Representative images of *smn-1(rt280)* GFP expression in wild type and \[*mel-46(+)\#2*\] larval stage L4 animals. Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.013](10.7554/eLife.20752.013)10.7554/eLife.20752.014Figure 2---figure Supplement 2---source data 1.Raw Data for [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.Raw data and statistical analysis that correspond to GFP::SMN-1 quantification in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.014](10.7554/eLife.20752.014)

The interdependency we report, between SMN-1 and MEL-46 levels, may be specific to particular tissues and/or neural circuits. For example, pharyngeal pumping rate defects were not ameliorated in *smn-1(ok355)* animals by increased *mel-46* levels (\[*mel-46(+)*\#1\] rescue array, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), suggesting a privileged relationship between SMN-1 and MEL-46 in cholinergic NMJ signaling. Increasing *mel-46* did rescue *smn-1(ok355)* synaptic protein localization defects. Using the \[*mel-46(+)*\#1\] rescue array, we rescued *smn-1(ok355)* defective SNB-1 puncta width and intensity to normal levels, but did not ameliorate linear density defects ([Figure 2F--J](#fig2){ref-type="fig"}). Notably, increased *mel-46* in an *smn-1(+)* control background did not increase SNB-1 levels, suggesting that *mel-46-*induced up-regulation of SNB-1 is specifically beneficial in a *smn-1(ok355)* background. Increasing *mel-46* with a second broadly-expressed *mel-46* rescue array line, \[*mel-46(+)*\#2\], also restored APT-4 puncta linear density to normal levels ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}), without rescuing other metrics. These results are consistent with the aldicarb/NMJ functional rescue studies presented here and suggest increasing *mel-46* improves neuromuscular signaling in *smn-1(ok355)* animals by partially restoring levels and localization of synaptic proteins. Furthermore, these results suggest that *mel-46* may act with or downstream of *smn-1* in a pathway essential for NMJ function.

Alternatively, we considered the possibility that increasing *mel-46* stabilizes maternally-loaded SMN-1 protein and mRNA, a scenario which could also explain *mel-46* rescue of *smn-1(ok355)* NMJ function. Since mammalian Gemin3 directly binds SMN ([@bib8]), increasing MEL-46 (Gemin3) might decrease the rate of SMN-1 loss. To test this possibility, we used CRISPR/Cas9-targeted genome editing to insert GFP coding sequences at the N-terminus of *smn-1* on chromosome I, resulting in fluorescent SMN-1 protein ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) ([@bib14]). The GFP-tagged protein was functional; animals were viable and fertile. We found that increasing *mel-46* using the \[*mel-46(+)*\#2\] rescue array did not increase GFP::SMN-1 levels, but unexpectedly caused a modest overall decrease ([Figure 2---figure supplement 2B and C](#fig2s2){ref-type="fig"}). It therefore seems unlikely that *smn-1(ok355)* rescue by increased *mel-46* is due to stabilization of maternally-loaded SMN-1. Using the same CRISPR-based method, we were unable to tag endogenous *smn-1* on balancer chromosomes necessary for maintaining the *smn-1(ok355)* line. This approach would have allowed us to examine the effects of MEL-46 overexpression on the stability of maternally-loaded SMN-1 in *smn-1(ok355)* animals. Therefore, although we cannot rule out stability of maternally-loaded SMN-1 as a contributing factor, the large effect that decreased SMN-1 has on MEL-46 localization favors a mechanism in which MEL-46 overexpression rescues *smn-1(ok355)* defects, at least in part, by restoring MEL-46 functional deficits in this background.

*C.elegans* miR-2 is required for NMJ function {#s2-3}
----------------------------------------------

The pathways in MNs downstream of SMN and Gemin3 that are linked to SMA are unknown. Here, we consider a role for these two proteins in miRNA regulation. As mammalian Gemin3 co-localizes and co-purifies with RISC pathway components ([@bib38]; [@bib37]; [@bib59]; [@bib62]; [@bib63]), we considered a role for miRNA regulation in NMJ function. miRNA miR-2 is enriched in neurons, expressed at all developmental stages, and predicted to regulate expression of many proteins involved in neuronal development and function ([@bib55]; [@bib56]). We hypothesized that miR-2 is necessary for proper NMJ function and that it might be perturbed by loss of either SMN-1 or MEL-46. To test this possibility, we first examined the aldicarb response of *mir-2(lf)* animals. Two different deletion alleles, *gk259* and *n4108*, caused resistance to aldicarb paralysis compared to wild type animals ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). This defect was partially rescued by expressing miR-2 under the control of a the *unc-17* (ACh) cholinergic neuron-specific promoter (referred to as (\[ACh::*mir-2(+)*\]) ([Figure 3A](#fig3){ref-type="fig"}). Loss of miR-2 also resulted in a mild pharyngeal pumping defect ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Taken together, we conclude that miR-2 is required in cholinergic neurons for proper NMJ signaling.10.7554/eLife.20752.015Figure 3.miR-2 is required in cholinergic neurons for proper NMJ function.(**a**) *mir-2(gk259)* animals were resistant to paralysis by aldicarb. Expression of miR-2 behind the *unc-17* (ACh) cholinergic promoter partially restored *mir-2(gk259)* sensitivity to aldicarb compared to transgenesis controls expressing GFP behind the same promoter. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mir-2(gk259), mir-2(gk259);*\[*ACh::mir-2(+)*\] and *mir-2(gk259);*\[*ACh::GFP*\] young adult animals. Log-rank test. (**b**) *mir-2(gk259)* animals had increased RFP::SNB-1 (synaptobrevin) linear density. Percent change from wild type (N2) control for RFP::SNB-1 in the dorsal nerve cord of *mir-2(gk259)* animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). *t*-test, two-tailed. (**c--d**) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal cord of wild type and *mir-2(gk259)* animals. These images were taken as part of data collection. Scale bar, 5 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.015](10.7554/eLife.20752.015)10.7554/eLife.20752.016Figure 3---source data 1.Raw Data for [Figure 3](#fig3){ref-type="fig"}.Raw data and statistical analysis that correspond to aldicarb resistance assays and RFP::SNB-1 localization analysis in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.016](10.7554/eLife.20752.016)10.7554/eLife.20752.017Figure 3---figure supplement 1.miR-2 is required for NMJ function.(**a**) *mir-2(n4108)* animals were resistant to the acetylcholinesterase inhibitor, aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2) and *mir-2(n4108)* young adult animals. Log-rank test. (**b**) *mir-2(gk259)* animals had reduced pharyngeal pumping rates *versus* wild type control. Mean ± SEM; *t*-test, two-tailed. (**c**) *mir-2(gk259)* SYD-2 (α-liprin) levels were indistinguishable from wild type (N2). Percent change from wild type control for SYD-2 in the dorsal nerve cord of *mir-2(gk259)* animals for 'punctaanalyzer' parameters: average puncta width (μm), total intensity (AU), and linear density (number/μm). *t*-test, two-tailed. (**d**) *mir-2(lf)* had reduced expression of ITSN-1 (DAP160/Intersectin). Percent change from wild type (N2) control for ITSN-1 in the dorsal nerve cord of *mir-2(gk259)* and *mir-2(n4108)* animals as above. *t*-test, two-tailed. (**e--f**) Representative images of ITSN-1::GFP expressed in the dorsal nerve cord of cholinergic DA motor neurons for wild type and *mir-2(n4108)* animals. These images were taken as part of data collection. Scale bar, 5 μm. (**g**) *mir-2(gk259)* and *mir-2(n4108)* animals had reduced APT-4 (AP2 α-adaptin) levels. Percent change from wild type (N2) control for the APT-4 in *mir-2(gk259)* animals as above. *t*-test, two-tailed. (**h--i**) Representative images of cholinergic DA motor neuron APT-4::GFP in the dorsal cord of wild type (N2) and *mir-2(gk259)* animals. These images were taken as part of data collection.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.017](10.7554/eLife.20752.017)10.7554/eLife.20752.018Figure 3---figure Supplement 1---source data 1.Raw Data for [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.Raw data and statistical analysis that correspond to SYD-2::GFP localization analysis, ITSN-1::GFP localization analysis, APT-4::GFP analysis, aldicarb resistance and pumping assays in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.018](10.7554/eLife.20752.018)

As a first step towards evaluating how miR-2 loss impacts cholinergic MN presynaptic function, we examined the effects of miR-2 loss on localization of presynaptic proteins in DA MNs. Four fluorescently-tagged presynaptic proteins were examined: SNB-1 (synaptobrevin), SYD-2 (α-liprin), ITSN-1 (DAP160/Intersectin), and APT-4 (AP2 α-adaptin). Analysis of tagged SNB-1 in *mir-2(gk259)* animals revealed increased SNB-1 puncta linear density, but no change in puncta width or intensity compared to wild type animals ([Figure 3B--D](#fig3){ref-type="fig"}). Additionally, *mir-2(gk259)* animals were indistinguishable from wild type control animals with respect to SYD-2 synaptic localization for all metrics analyzed ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), suggesting that pre-synaptic active zones are unchanged in number and size; thus, synaptic changes are likely not the result of altered active zone number or size ([@bib99]). ITSN-1 puncta width and intensity, but not linear density, were decreased in *mir-2(gk259)* and *mir-2(n4108),* animals compared to wild type controls ([Figure 3---figure supplement 1D--F](#fig3s1){ref-type="fig"}). Finally, both *mir-2(gk259)* and *mir-2(n4108)* had decreased APT-4 puncta width, intensity, and linear density ([Figure 3---figure supplement 1G--I](#fig3s1){ref-type="fig"}). ITSN-1, similar to APT-4, is involved in vesicle recycling at the NMJ ([@bib88]). Together with results from aldicarb resistance studies, our results suggest that loss of miR-2 results in synaptic dysfunction at the NMJ, consistent with decreased cholinergic synaptic release ([@bib7]; [@bib76]). Additionally, we observed considerable overlap between synaptic protein localization defects resulting from miR-2 loss with those of *smn-1(ok355)* animals ([@bib17]), a finding consistent with miR-2 and SMN-1 acting in partially redundant pathways at the NMJ.

*C.elegans* miR-2 targets *gar-2* mRNA in cholinergic neurons {#s2-4}
-------------------------------------------------------------

To address mechanistically how miR-2 loss impacts NMJ function, we searched for mRNA targets of miR-2. Canonically, miRNA loss results in overexpression of direct mRNA targets ([@bib21]). Since miR-2 loss leads to aldicarb resistance, loss of the target(s) is expected to cause hypersensitivity to aldicarb. Following a literature search for genes whose loss of function results in hypersensitivity, we selected the following genes with putative miR-2 3'UTR binding sites for study: *gar-2*, *dbl-1*, *sek-1*, and *vab-2* ([@bib41]; [@bib52]; [@bib66]; [@bib71]; [@bib87]). Loss of a *bona fide* target gene is predicted to suppress aldicarb resistance caused by miR-2 loss. Therefore, we crossed a deletion allele for each gene into the *mir-2(gk259)* background. Loss of any of these four genes suppressed *mir-2(gk259)* to some extent, but *gar-2(ok520),* which contains a large deletion removing *gar-2* exons 6 and 7, resulted in the most complete suppression, thus suggesting that GAR-2 acts downstream of miR-2 ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). GAR-2 is a G protein-coupled acetylcholine receptor orthologous to the mammalian M2 muscarinic receptor (m2R) ([@bib49]).10.7554/eLife.20752.019Figure 4.miR-2 binds the gar-2 3'UTR and represses GAR-2 translation.(**a**) Loss of m2R ortholog, GAR-2, suppressed aldicarb response defects of animals lacking *mir-2(gk259). gar-2(ok520)* animals were hypersensitive to paralysis by aldicarb. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mir-2(gk259), gar-2(ok520)* and *mir-2(gk259);gar-2(ok520)* young adult animals. Log-rank test. (**b**) Schematic representation of changes made to the endogenous *gar-2* 3'UTR using CRISPR. For the wild type control (*gar-2* UTRwt^C^), the miR-2 binding site remained intact, however, a C\>T PAM site change was made. For the experimental condition (*gar-2* UTRscr^C^), the miR-2 binding site was scrambled in addition to the C\>T PAM site alteration. (**c**) *gar-2*(*rt318)*, referred to as *gar-2* UTRscr^C^, animals were resistant to the acetylcholinesterase inhibitor, aldicarb, compared to *gar-2(rt317),* referred to as *gar-2* UTRwt^C^. Time course for paralysis on 1 mM aldicarb for young adult animals. Log-rank test. (**d**) Scrambling the predicted endogenous *gar-2* 3'UTR miR-2 binding site increased *gar-2* messenger RNA levels. Quantification of *gar-2* mRNA levels in young adult *gar-2* UTRwt^C^ and *gar-2* UTRscr^C^ animals. *t-*test, two-tailed (n = 4 for *gar-2* UTRwt^C^ and *gar-2* UTRscr^C^). (**e**) Reporter constructs used to assess miR-2 regulation of *gar-2* 3'UTR in cholinergic neurons: *rtIs56* (*unc-17*p-ACh::GFP::*gar-2* 3'UTRwt) and *rtIs57* or *rtIs58* (*unc-17*p-ACh::GFP::*gar-2* 3'UTRscr). *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt construct contains the *unc-17* promoter expressing NLS::GFP upstream of the *gar-2* 3'UTR, which has a predicted miR-2 binding site. Red text indicates intact seed region. *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr is the same construct with the predicted miR-2 binding site scrambled identically to the sequence in *gar-2* UTRscr^C^ animals. (**f**) Representative images of *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt expression in cholinergic neurons of wild type (N2) and *mir-2(gk259)* larval stage L4 animals. Scale bar, 50 μm. (**g**) Representative images of *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr (*rtIs57*) expression in cholinergic neurons of wild type (N2) and *mir-2(gk259)* larval stage L4 animals. (**h**) Ratio representation of mean GFP fluorescence for wild type and *mir-2(gk259)* animals. *t*-test, two-tailed. Ratio was calculated by dividing the mean GFP fluorescence of *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt for each genotype by the corresponding mean GFP fluorescence of *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr for that genotype. UTRwt represents mean fluorescence for each genotype expressing the *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt reporter, while UTRscr represents mean fluorescence for each genotype expressing the *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr control reporter. Error bars represent the cumulative SEM for each genotype across transgenes. (see [Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). (**i**) *gar-2* transcript levels did not increase in a *mir-2* loss of function background. Quantification of *gar-2* mRNA levels in young adult *mir-2(gk259)* animals compared to wild type (N2) controls. *t-test*, two-tailed (n = 4 for *mir-2(gk259)* and N2).**DOI:** [http://dx.doi.org/10.7554/eLife.20752.019](10.7554/eLife.20752.019)10.7554/eLife.20752.020Figure 4---source data 1.Raw Data for [Figure 4](#fig4){ref-type="fig"}.Raw data and statistical analysis that correspond to aldicarb resistance assays, qPCR quantification, and GFP reporter analysis in [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.020](10.7554/eLife.20752.020)10.7554/eLife.20752.021Figure 4---figure supplement 1.Loss of predicted miR-2 mRNA targets suppresses *mir-2(lf)* aldicarb resistance.(**a**) Loss of DBL-1 suppressed *mir-2(gk259)* aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mir-2(n4108), mir-2(n4108);dbl-1(nk3),* and *dbl-1(nk3)* young adult animals. Log-rank test. (**b**) Loss of SEK-1 suppressed *mir-2(gk259)* aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mir-2(n4108), mir-2(n4108);sek-1(km4),* and *sek-1(km4)* young adult animals. Log-rank test. (**c**) Loss of VAB-2 suppressed *mir-2(gk259)* aldicarb resistance. Time course for paralysis on 1 mM aldicarb for wild type (N2), *mir-2(n4108), mir-2(n4108);vab-2(ju1),* and *vab-2(ju1)* young adult animals. Log-rank test.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.021](10.7554/eLife.20752.021)10.7554/eLife.20752.022Figure 4---figure Supplement 1---source data 1.Raw Data for [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.Raw data and statistical analysis that correspond to aldicarb resistance assays in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.022](10.7554/eLife.20752.022)10.7554/eLife.20752.023Figure 4---figure supplement 2.miR-2 inhibits translation by binding the *gar-2* 3'UTR.(**a**) Loss of *miR-2* results in increased expression of *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt. *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt mean GFP fluorescence in wild type (N2) and *mir-2(gk259)* backgrounds. Mean ± SEM; *t*-test, two-tailed. (**b--c**) Expression of *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr was indistinguishable in *mir-2(gk259) versus* wild type (N2) animals for two independent integrated lines. *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr mean GFP fluorescence in wild type (N2) and *mir-2(gk259)* backgrounds. Mean ± SEM; *t*-test, two-tailed. (**d**) Formula used to calculate the ratio and standard error of the mean (SEM) shown in [Figure 4](#fig4){ref-type="fig"}. UTRwt represents mean fluorescence for each genotype expressing the *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt reporter, while UTRscr represents mean fluorescence for each genotype expressing the *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr control reporter. For SEM, *s* represents the standard deviation of the population and n represents the number of animals analyzed.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.023](10.7554/eLife.20752.023)10.7554/eLife.20752.024Figure 4---figure Supplement 2---source data 1.Raw Data for [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}.Raw data and statistical analysis that correspond to GFP reporter analysis in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.024](10.7554/eLife.20752.024)

To determine if miR-2 regulates GAR-2 expression directly, we examined the consequences of perturbing the putative miR-2 binding site in the *gar-2* 3'UTR. Using CRISPR/Cas9-targeted genome editing, we scrambled the 18 base pair *gar-2* 3'UTR region corresponding to the endogenous miR-2 binding site ([Figure 4B](#fig4){ref-type="fig"}). Compared to control animals (*gar-2* UTRwt^C^) carrying the disrupted PAM site mutation (C\>T), we found that animals with the scrambled miR-2 binding site (*gar-2* UTRscr^C^) were resistant to aldicarb, similar to miR-2 loss ([Figure 4C](#fig4){ref-type="fig"}). To evaluate whether disruption of the miR-2 binding site influenced *gar-2* transcript levels, we compared *gar-2* mRNA levels in *gar-2* UTRscr^C^ animals and *gar-2* UTRwt^C^ controls and found a 40% increase in *gar-2* transcript in *gar-2* UTRscr^C^ ([Figure 4D](#fig4){ref-type="fig"}). Disruption of the 3'UTR site likely inhibits binding of other miR-2 family members, possibly contributing to the effect we observe ([@bib39]).

To test the effects of miR-2 loss on GAR-2 function in cholinergic neurons, we undertook in vivo GFP reporter analysis of GAR-2 expression. We generated a construct encoding GFP with a *gar-2* 3'UTR, whose expression is driven under the control of a cholinergic-specific promoter (referred to as *unc-17p-*ACh::GFP::*gar-2* 3'UTRwt). A second control version of the construct contained the same scrambled UTR sequence as used in *gar-2* UTRscr^C^ animals (referred to as *unc-17p-*ACh::GFP::*gar-2* 3'UTRscr) ([Figure 4E](#fig4){ref-type="fig"}). Transgenic lines were created by multicopy insertion for each construct. Increased GFP levels were observed in *mir-2(gk259)* animals expressing the intact 3'UTR construct as compared to control animals ([Figure 4F](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). Whereas, loss of the *mir-2* gene did not affect GFP levels in animals expressing the scrambled 3'UTR construct compared to control ([Figure 4G](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2B and C](#fig4s2){ref-type="fig"}). To quantify impact of miR-2 on expression of these GFP reporters in various genetic backgrounds, we compared relative changes in GFP levels of transgenic lines using a ratiometric strategy; we determined GFP expression for lines carrying *unc-17p-*ACh::GFP::*gar-2* 3'UTRwt and compared these values to lines carrying *unc-17p-*ACh::GFP::*gar-2* 3'UTRscr in the same genetic background ([Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). By this method, we observed a \~13% increase in relative GFP expression associated with loss of miR-2 ([Figure 4H](#fig4){ref-type="fig"}), indicating that miR-2 directly suppresses translation of *gar-2* mRNA by binding the *gar-2* 3'UTR at this 3'UTR site. We also assessed the effect of miR-2 loss on *gar-2* transcript levels and found no significant difference in *gar-2* mRNA levels between wild type animals and *mir-2(gk259)* loss of function animals ([Figure 4I](#fig4){ref-type="fig"}). These results, combined with our reporter data, suggest that miR-2 binds and inhibits *gar-2* mRNA translation, but does not reduce transcript levels. Previous studies have reported that miRNAs can influence protein synthesis of targets without destabilizing mRNA levels ([@bib10]; [@bib75]).

miR-2 suppression of *gar-2* is disrupted by smn-1 loss {#s2-5}
-------------------------------------------------------

Next, we determined if *smn-1* loss altered miR-2 regulation of the *gar-2* 3'UTR. Both GFP reporter transgenes were crossed into the *smn-1(ok355)* background. Using the same ratiometric strategy from [Figure 4H](#fig4){ref-type="fig"}, we observed a small increase in relative GFP reporter expression (\~5%) in *smn-1(ok355)* animals compared to *smn-1(+)* controls ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). This finding suggested that *smn-1(ok355)* animals may have decreased miR-2 function and, as a consequence, an increase in GAR-2 translation. We showed above that increased *mel-46* levels ameliorates *smn-1(ok355)* NMJ defects ([Figure 2](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), therefore we assessed the impact of increased *mel-46* on miR-2 activity using the \[*mel-46(+)*\#2\] rescue array. In control *smn-1(+)* animals, increasing *mel-46* did not alter relative expression of the miR-2 GFP reporter. However, in *smn-1(ok355)* animals, increasing *mel-46* caused decreased relative reporter expression by \~15%, compared to *smn-1(ok355)* animals lacking the *mel-46* rescue array ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). These data suggest that MEL-46 overexpression decreases GAR-2 levels in *smn-1(ok355)* by increasing miR-2 activity.10.7554/eLife.20752.025Figure 5.*smn-1* loss of function abrogated miR-2 repression of GAR-2 expression.(**a**) Loss of *smn-1* caused a relative increase in *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt expression. Expressing *mel-46* using the broadly expressed \[*mel-46(+)\#2*\] array decreased relative *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt expression in *smn-1(ok355)* animals. Ratio representation of mean GFP fluorescence for *smn-1(+), smn-1(ok355), smn-1(ok355);*\[*mel-46(+)\#2*\], and *smn-1(+);*\[*mel-46(+)\#2*\] animals. Mann-Whitney *U*-test, two-tailed. Ratio calculation was completed in the same manner as [Figure 4H](#fig4){ref-type="fig"} (see also [Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}) (**b**) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(*RNAi*), *smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping miRNA miR-60. *t-*test, two-tailed (n = 6 for each condition). (**c**) *gar-2* transcript levels did not change when SMN-1 or MEL-46 levels decreased in neurons. Quantification of *gar-2* mRNA for empty(*RNAi*), *smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals. *t-*test, two-tailed (n = 3 for each condition). (**c--d**) Animals sensitive to RNAi in only neurons (TU3401) were fed bacteria expressing double-stranded RNA (dsRNA) against *mel-46* or *smn-1.* Control animals were fed bacteria expressing an empty vector control: empty(*RNAi*).**DOI:** [http://dx.doi.org/10.7554/eLife.20752.025](10.7554/eLife.20752.025)10.7554/eLife.20752.026Figure 5---source data 1.Raw data for [Figure 5](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.026](10.7554/eLife.20752.026)10.7554/eLife.20752.027Figure 5---figure supplement 1.Increasing MEL-46(Gemin3) ameliorates *smn-1(lf)* defective miR-2 activity.(**a**) Expression of mean *unc-17*p-ACh::GFP::*gar-2* 3'UTRscr (*rtIs57*) fluorescence was decreased in *smn-1(ok355)* compared to *smn-1(+)* control animals. Increasing MEL-46 levels using the \[*mel-46(+)\#2*\] array did not alter expression *versus smn-1(+)* controls. Mean *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt fluorescence in *smn-1(+), smn-1(ok355), smn-1(ok355);*\[*mel-46(+)\#2*\], and *smn-1(+);*\[*mel-46(+)\#2*\] animals. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**b**) Expression of mean *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt fluorescence was indistinguishable between *smn-1(+)* and *smn-1(ok355)* animals; increasing MEL-46 using the \[*mel-46(+)\#2*\] array reduced expression *versus* control. Mean *unc-17*p-ACh::GFP::*gar-2* 3'UTRwt fluorescence in *smn-1(+), smn-1(ok355), smn-1(ok355);*\[*mel-46(+)\#2*\], and *smn-1(+);*\[*mel-46(+)\#2*\] animals. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**c**) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(*RNAi*), *smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping gene *act-1. t-*test, two-tailed (n = 6 for each condition). (**d**) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty(*RNAi*), *smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping rRNA 18s. *t-*test, two-tailed (n = 6 for each condition).**DOI:** [http://dx.doi.org/10.7554/eLife.20752.027](10.7554/eLife.20752.027)10.7554/eLife.20752.028Figure 5---figure Supplement 1---source data 1.Raw Data for [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.Raw data and statistical analysis that correspond to GFP reporter analysis and qPCR quantification in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.028](10.7554/eLife.20752.028)

Increased GAR-2 translation in animals lacking SMN-1 might be due to decreased mature miR-2 levels. To test this possibility, we used quantitative RT-PCR studies. After neuron-specific RNAi knock-down of either SMN-1 or MEL-46, we found decreases in mature miR-2 levels ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}), but no change in *gar-2* transcript levels ([Figure 5C](#fig5){ref-type="fig"}). This result is consistent with our finding that *gar-2* transcript levels were unchanged in miR-2 complete loss conditions ([Figure 4I](#fig4){ref-type="fig"}), despite alterations in GFP reporter expression ([Figure 4H](#fig4){ref-type="fig"}). These results suggest neuronal miR-2 levels are decreased when MEL-46 or SMN-1 levels decrease.

Collectively, our data above are consistent with a model where diminished SMN-1 leads to decreased miR-2 levels and activity, resulting in increased GAR-2 expression. Since M2 receptors inhibit synaptic release at cholinergic NMJs across species ([@bib18]; [@bib67]; [@bib79]), overexpression of these receptors in *smn-1(ok355)* MNs might contribute to the NMJ defects previously observed in these animals ([@bib17]; [@bib78]). Furthermore, increased MEL-46/Gemin3 might have an ameliorative effect in animals lacking SMN-1 by stimulating miR-2 activity, thus decreasing GAR-2 levels and disinhibiting cholinergic release.

*gar-2* loss ameliorates *smn-1(lf)* neuromuscular defects {#s2-6}
----------------------------------------------------------

If increased GAR-2 levels exacerbate NMJ dysfunction in animals lacking SMN-1, then decreasing GAR-2 function should ameliorate the NMJ defects caused by *smn-1* loss of function. Loss of GAR-2 did not improve pharyngeal pumping rates in *smn-1(ok355)* animals ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), similar to our results in animals with increased *mel-46* levels ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). However, similar to increasing *mel-*46, *gar-2(ok520)* restored normal response to aldicarb in both *smn-1(ok355)* and *smn-1(rt248)* animals ([Figure 6A](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), consistent with improved NMJ function. The *rt248 smn-1* allele causes a frameshift and loss of SMN-1 function similar to *ok355* ([@bib17]). Additionally, *gar-2(ok520)* restored normal response to aldicarb in *mel-46(tm1739)* animals ([Figure 6B](#fig6){ref-type="fig"}). Our results indicate that decreasing GAR-2 likely improves presynaptic function in animals with decreased SMN-1 or MEL-46. Consistent with this conclusion, *gar-2(ok520)* also rescued numerous presynaptic protein localization defects caused by SMN-1 loss; SNB-1 puncta width, intensity and linear density defects were rescued in both *smn-1(ok355)* and *smn-1(rt248)* backgrounds ([Figure 6C--6G](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1D--H](#fig6s1){ref-type="fig"}). GAR-2 loss in *smn-1(+)* control animals resulted in increased SNB-1 puncta width and intensity, but did not alter SNB-1 puncta linear density.10.7554/eLife.20752.029Figure 6.Loss of *gar-2* ameliorated *smn-1(lf)* NMJ defects.(**a**) Loss of *gar-2* rescued *smn-1(ok355)* aldicarb response defect. Time course for paralysis on 1 mM aldicarb for *smn-1(+)*, *smn-1(ok355), smn-1(ok355);gar-2(ok520),* and *smn-1(+);gar-2(ok520)* early larval stage L4 animals. Log-rank test. (**b**) Loss of *gar-2* rescued *mel-46(tm1739)* aldicarb response defect. Time course for paralysis on 1 mM aldicarb for *mel-46(+)*, *mel-46(tm1739), mel-46(tm1739);gar-2(ok520),* and *smn-1(+);gar-2(ok520)* early larval stage L4 animals. Log-rank test. For these experiments, *mel-46(tm1739)* was maintained over the *nT1* balancer and therefore, control *mel-46(+)* animals were obtained as +/+ animals from +/*nT1* heterozygous mothers. (**c**) Loss of *gar-2* rescued *smn-1(ok355)* RFP::SNB-1 synaptic localization defects. *gar-2* loss in the *smn-1(+)* background resulted in increased RFP::SNB-1 puncta width and intensity. Percent change from *smn-1(+)* control for RFP::SNB-1 in the dorsal nerve cord of *smn-1(ok355), smn-1(ok355);gar-2(ok520),* and *smn-1(+);gar-2(ok520)* animals for 'punctaanalyzer' parameters: puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to *smn-1(+)* control; shading indicates significant difference from *smn-1(ok355);gar-2(ok520).* Mann-Whitney *U*-test, two-tailed. Loss of *gar-2* rescued RFP::SNB-1 puncta width defects (*smn-1(+)* control animals *versus smn-1(ok355);gar-2(ok520) p=*0.76; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.0001), restored SNB-1 puncta intensity (*smn-1(+)* control animals *versus smn-1(ok355);gar-2(ok520) p=*1.00; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.0001) and rescued SNB-1 puncta linear density defects (*smn-1(+)* control animals *versus smn-1(ok355);gar-2(ok520) p=*0.08; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.02). (**d--g**) Representative images of cholinergic DA MN RFP::SNB-1 in the dorsal nerve cord of *smn-1(+), smn-1(ok355), smn-1(ok355);gar-2(ok520),* and *smn-1(+);gar-2(ok520)*. These images were taken as part of data collection. Scale bar, 5 μm. Figures D and G are also shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} since this control data was collected alongside both *ok355* and *rt248* RFP::SNB-1 data.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.029](10.7554/eLife.20752.029)10.7554/eLife.20752.030Figure 6---source data 1.Raw Data for [Figure 6](#fig6){ref-type="fig"}.Raw data and statistical analysis that correspond to RFP::SNB-1 localization analysis and aldicarb resistance assays in [Figure 6](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.030](10.7554/eLife.20752.030)10.7554/eLife.20752.031Figure 6---figure supplement 1.Decreasing GAR-2(m2R) levels rescues NMJ defects in *smn-1(lf)* and *mel-46(lf)* animals.(**a**) *smn-1(ok355)* animals had reduced pharyngeal pumping rates *versus smn-1(+)* control animals; defects were not rescued by loss of GAR-2. Mean ± SEM; Mann-Whitney *U*-test, two tailed. (**b**) Loss of GAR-2 ameliorated *smn-1(rt248)* aldicarb response. *smn-1(+);gar-2(ok520)* animals were hypersensitive to aldicarb. Time course for paralysis on 1 mM aldicarb in *smn-1(+)*, *smn-1(rt248), smn-1(rt248);gar-2(ok520),* and *smn-1(+);gar-2(ok520)* early larval stage L4 animals. Log-rank test. (**c**) Loss of GAR-2 did not rescue *smn-1(ok355)* APT-4 (AP2 α-adaptin) defects. Loss of GAR-2 in the *smn-1(+)* background resulted in decreased APT-4 puncta width and intensity. Percent change from *smn-1(+)* control for APT-4 in the dorsal cord of *smn-1(ok355), smn-1(ok355);gar-2(ok520),* and *smn-1(+);gar-2(ok520)* animals for 'punctaanalyzer' parameters: average puncta width (μm), intensity (AU), and linear density (number/μm). Asterisks denote significance compared to *smn-1(+)* control. Mann-Whitney *U*-test, two-tailed. GAR-2 loss did not rescue APT-4 puncta width (*smn-1(+)* control *versus smn-1(ok355);gar-2(ok520) p=*0.12; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.48), did not rescue APT-4 puncta intensity (*smn-1(+)* control *versus smn-1(ok355);gar-2(ok520) p=*0.08; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.54) and did not rescue APT-4 puncta linear density (*smn-1(+)* control *versus smn-1(ok355);gar-2(ok520) p=*0.66; *smn-1(ok355) versus smn-1(ok355);gar-2(ok520) p=*0.07). (**d**) Loss of GAR-2 ameliorated *smn-1(rt248)* SNB-1 (synaptobrevin) defects. Percent change from *smn-1(+)* control for SNB-1 in the dorsal nerve cord of *smn-1(rt248),* and *smn-1(rt248);gar-2(ok520)* animals for all 'punctaanalyzer' parameters: average puncta width (μm), total intensity (AU), and linear density (number/μm). *smn-1(+);gar-2(ok520)* percent change was collected alongside this data and is shown in [Figure 5B](#fig5){ref-type="fig"}. Asterisks denote significance compared to *smn-1(+)* control; shading indicates significant difference from *smn-1(rt248);gar-2(ok520).* Mann-Whitney *U*-test, two-tailed. Loss of GAR-2 rescued SNB-1 puncta width (*smn-1(+)* control *versus smn-1(rt248);gar-2(ok520) p=*0.83; *smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=*0.004), restored SNB-1 total puncta intensity (*smn-1(+)* control *versus smn-1(rt248);gar-2(ok520) p=*0.91; *smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=*0.004) and rescued SNB-1 puncta linear density (*smn-1(+)* control *versus smn-1(rt248);gar-2(ok520) p=*0.97; *smn-1(rt248) versus smn-1(rt248);gar-2(ok520) p=*0.002). (Martinez et al.) Representative images of SNB-1::RFP expressed in the dorsal nerve cord of cholinergic DA motor neurons for *smn-1(+), smn-1(rt248), smn-1(rt248);gar-2(ok520),* and *smn-1(+);gar-2(ok520)*. These images were taken as part of data collection. Scale bar, 5 μm. Figures E and H were taken from [Figure 5](#fig5){ref-type="fig"} since this data was collected alongside both *ok355* and *rt248* SNB-1::RFP data.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.031](10.7554/eLife.20752.031)10.7554/eLife.20752.032Figure 6---figure Supplement 1---source data 1.Raw Data for [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.Raw data and statistical analysis that correspond to APT-4::GFP localization analysis, RFP::SNB-1 localization analysis, aldicarb resistance and pumping assays in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.032](10.7554/eLife.20752.032)

Research in vertebrates has demonstrated m2R internalization normally occurs in response to chronic m2R stimulation, either by pharmacological agonist application or acetylcholinesterase inhibition ([@bib9]). Since endocytosis is defective in animals lacking SMN-1, perturbed endocytosis, in combination with miRNA misregulation, could contribute to GAR-2 accumulation at the membrane leading to decreased SNB-1 in *smn-1(ok355)* motor neurons ([@bib17]). Loss of GAR-2 did not rescue *smn-1(ok355)* APT-4 puncta defects ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), but decreased APT-4 puncta width and intensity in *smn-1(+)* control animals. As loss of GAR-2 did not restore APT-4 synaptic defects, we conclude that there are additional pathways affected by *smn-1* loss, beyond GAR-2 misregulation. Nevertheless, these results suggest that *C. elegans* GAR-2 levels are increased by *smn-1* loss, which might contribute to NMJ defects in *smn-1(lf)* animals.

The GAR-2 mammalian ortholog, m2R, is increased in SMA mouse model motor neurons {#s2-7}
--------------------------------------------------------------------------------

The closest human ortholog of GAR-2 is the M2 muscarinic receptor (m2R), encoded by the *CHRM2* gene. GAR-2 and m2R are functionally conserved, as activation of these presynaptic receptors by acetylcholine in different species results in hyperpolarization and decreased NMJ acetylcholine release across species ([@bib18]; [@bib20]; [@bib67]; [@bib79]). Previous research suggests decreased SMN function across species might impact miRNA activity across species, which could increase m2R levels consistent with our work in *C. elegans.* The *CHRM2* mRNA is a predicted target of miR-128 in mice and humans ([Figure 7A](#fig7){ref-type="fig"}) ([@bib41]; [@bib52]; [@bib66]). Based on results from *C. elegans*, we predicted that vertebrate SMN loss might disrupt miR-128 activity, also leading to increased m2R. m2R protein levels were examined in MNs isolated from E13.5 SMA mice (*Smn*^-/-^;*SMN2*^tg/0^). A \~50% increase in m2R levels was observed, compared to wild type control MNs ([Figure 7B and C](#fig7){ref-type="fig"}). miR-128 levels in SMA mouse MNs were decreased compared to wild type ([Figure 7D](#fig7){ref-type="fig"}). Combined, these results suggest that diminished SMN protein causes decreased levels of mature miR-128, thus disinhibiting m2R expression in MNs across species.10.7554/eLife.20752.033Figure 7.Increased m2R muscarinic receptor levels in SMA mouse model MNs contribute to axon outgrowth defects.(**a**) Alignment of predicted miR-2 or miR-128 binding sites for *C. elegans,* mouse and human *gar-2* or *CHRM2* 3'UTRs. *CHRM2* encodes the mR2 muscarinic receptor ([@bib66]; [@bib71]). Predicted nucleotide pairing shown by vertical lines. Red text indicates predicted miRNA seed region. A black line indicates potential seed region conservation. (**b**) Representative image for two E13.5 wild type and two *Smn*^-/-^;*SMN2*^tg/0^ DIV10 spinal MN immunoblots probed for m2R and control β-Actin. (**c**) Quantification of immunoblot, *t*-test, two-tailed, p*=*0.017 (n = 14 for WT and n = 13 for SMA). (**d**) Quantification of miR-128 levels in DIV10 spinal MNs from E13.5 wild type and *Smn*^-/-^;*SMN2*^tg/0^ animals. *t*-test, two-tailed (n = 24 from 12 mice for WT; n = 20 from 10 mice for SMA). (**e**) Longest axon length for E13.5 wild type and *Smn*^-/-^;*SMN2*^tg/0^ DIV5 spinal MNs treated with 0 nm, 50 nm, and 500 nm methoctramine. *t-*test, two-tailed. (n = 103 for WT 0 nM, n = 131 for WT 50 nM, n = 98 for WT 500 nM, n = 102 for SMA 0 nM, n = 67 for SMA 50 nM and n = 53 for SMA 500 nM) (**f**) Proposed model: SMN acts via MEL-46 to influence microRNAs that play important roles in NMJ function and MN survival. SMN loss affects other pathways as well. *C. elegans* genes shown on left side; human genes on right side.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.033](10.7554/eLife.20752.033)10.7554/eLife.20752.034Figure 7---figure supplement 1.m2R inhibition by methoctramine increases axon length in SMA mouse model MNs.(**a**) Total axon length for E13.5 wild type and *Smn*^-/-^;*SMN2*^tg/0^ DIV5 spinal MNs treated with 0 nm, 50 nm, and 500 nm methoctramine. 'Total axon length' is a measurement of all axon branches. *t-*test, two-tailed. n = 103 for WT 0 nM, n = 131 for WT 50 nM, n = 98 for WT 500 nM, n = 102 for SMA 0 nM, n = 67 for SMA 50 nM and n = 53 for SMA 500 nM. Neurons are from at least three biological samples.**DOI:** [http://dx.doi.org/10.7554/eLife.20752.034](10.7554/eLife.20752.034)

Inhibition of m2R by methoctramine rescued axon outgrowth defects in SMA mouse model MNs {#s2-8}
----------------------------------------------------------------------------------------

Decreased SMN levels results in axon outgrowth defects in MNs derived from a SMA mouse model ([@bib73]) and increased m2R might contribute to this functional defect. To test this, we examined the impact of m2R pharmacological inhibition on axon length for DIV5 MNs from E13.5 wild type (FVB) and SMA mice (*Smn*^-/-^;*SMN2*^tg/0^) ([Figure 7E](#fig7){ref-type="fig"}). Wild type and SMA MNs were cultured in the presence of 50 nm or 500 nm methoctramine, an m2R antagonist. In wild type MNs, methoctramine decreased mean longest axon length. Conversely, methoctramine treatment in SMA MNs increased both mean longest axon length and total axon length ([Figure 7E](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). We conclude that m2R inhibition rescues MN axon outgrowth defects in a SMA mouse model, consistent with a deleterious impact of increased m2R activity in SMA model MNs.

Discussion {#s3}
==========

Our understanding of the mechanisms by which SMN loss influences MN function and survival remains incomplete. Many pathways are perturbed by SMN loss, including spliceosome assembly, pre-mRNA splicing, mRNA transport, endocytosis, and axon growth ([@bib17]; [@bib23]; [@bib35]; [@bib57]; [@bib58]; [@bib69]). As the human *CHRM2* locus lacks introns ([@bib31]), spliceosomal defects caused by SMN1 loss of function are unlikely to directly affect mature *CHRM2* mRNA levels, although indirect effects are possible. Based on our results, the simplest model explaining why SMN loss alters m2R levels is one in which decreased SMN levels impact Gemin3 function, thus perturbing miRNA pathways, including miR-128 suppression of m2R translation. As m2R receptors inhibit cholinergic MN synaptic release ([@bib79]), m2R up-regulation may contribute to MN defects in early stages of SMA pathogenesis, in parallel to perturbation of other pathways affected by SMN loss ([Figure 7F](#fig7){ref-type="fig"}).

SMN-1 loss impacts miRNA activity in *C. elegans* potentially via MEL-46/Gemin3 {#s3-1}
-------------------------------------------------------------------------------

The most direct molecular connection between SMN and the miRNA pathway is Gemin3. Results presented here indicate that decreases in SMN-1(SMN) or MEL-46(Gemin3) result in similar neuromuscular defects as well as decreased miR-2 levels in neurons. This analysis further suggests that decreases in *C. elegans* SMN-1 result in increased GAR-2 (m2R) through miR-2 misregulation and that increasing MEL-46 (Gemin3) reduces GAR-2 protein levels in *smn-1(ok355)* animals *via* modulation of miR-2. Several lines of evidence support this conclusion, including miR-2 GFP reporter expression results, NMJ aldicarb sensitivity, synaptic protein localization changes, and qPCR measurements of mature miR-2 and *gar-2* mRNA levels ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}).

There is a paucity of research addressing the functional importance of Gemin3, in either the Gemin or the RISC complexes. Biochemical and co-localization studies support a role for Gemin3 in spliceosome assembly, mRNA transport, and miRNA function ([@bib8]; [@bib19]; [@bib24]; [@bib62]; [@bib98]). It is possible that decreased and/or mislocalized Gemin3 impairs RISC function, leading to the diminished miR-2 activity and levels reported in [Figure 5](#fig5){ref-type="fig"}. However, since Gemin3 likely functions in numerous pathways, it may influence miR-2 through other, more indirect pathways. In *Drosophila*, Gemin3 is necessary for motor function, but the molecular mechanisms underlying this defect are unclear ([@bib6]). Results presented here in *C. elegans* further support a requirement for Gemin3 in motor function and additionally, show that Gemin3 is capable of modifying miRNA levels and activity.

SMN depletion results in miRNA misregulation across species {#s3-2}
-----------------------------------------------------------

miR-2 belongs to the invertebrate K box family (motif: CUGUGAUA) of miRNAs ([@bib39]). It was suggested previously that miR-2 does not have well-conserved mammalian orthologs ([@bib55]), but another study suggested that human miR-128 is a member of this miRNA family ([@bib39]). These two bioinformatics studies differ in their definition of the miRNA binding site, also known as the seed region. Our alignment of miR-2/miR-128 miRNAs and *gar-2/CHRM2* mRNAs suggests that the CUGUG seed region may be a conserved motif for miRNA binding ([Figure 7A](#fig7){ref-type="fig"}). Both miR-2 and miR-128 are enriched in the nervous system and share conserved mRNA targets ([@bib55]; [@bib56]). More studies will be needed to confirm that miR-2 and miR-128 are orthologs. Regardless, the results presented here, in conjunction with previous research, suggest that overall miRNA misregulation contributes to neuronal defects when SMN levels decrease ([@bib33]; [@bib48]; [@bib86]; [@bib89]; [@bib92]).

Altered function of miR-2/miR-128 or GAR-2/m2R is not sufficient to explain all of the dysfunction observed in models of SMN deficiency. In *C. elegans,* miR-2 loss does not cause overt defects and GAR-2 loss does not restore viability, fecundity, or normal development to animals lacking SMN-1 or MEL-46. This suggests miR-2 loss does not contribute to defects outside the NMJ caused by SMN-1 loss. And, at the NMJ, synaptic protein perturbations are more severe in animals with diminished SMN-1 or MEL-46, compared to those lacking either miR-2 or GAR-2, which is consistent with a broader range of defects caused by decreased SMN-1 levels. In mice, complete miR-128 knock-out results in decreased motor activity and premature death ([@bib82]), but it is currently unknown how miR-128 loss might specifically impact cholinergic MN function.

M2 receptor expression is increased in SMA model MNs {#s3-3}
----------------------------------------------------

We found that m2R levels were increased 50% overall in SMN-deficient mouse MNs compared to wild type by Western blot analysis ([Figure 7B and C](#fig7){ref-type="fig"}). In *C. elegans*, relative GAR-2 translation was increased by only 5% globally when SMN-1 levels dropped, based on GFP reporter expression in cholinergic neurons ([Figure 5A](#fig5){ref-type="fig"}). These two assays are not directly comparable, since the *C. elegans* experiment only investigated the contribution of miR-2 perturbation in regards to increased GAR-2 translation. Certainly, additional pathways are affected by SMN loss, beyond miRNAs, contributing to the greatly increased m2R levels in SMN-deficient MNs. These pathways may include mRNA transport metabolism, endocytosis, as well as spliceosome and ribonucleoprotein assembly ([@bib17]; [@bib23]; [@bib35]; [@bib69]; [@bib96]). Extensive analysis would be required to understand how defects in these pathways contribute to increased m2R in SMN-deficient MNs.

Could increased M2 muscarinic receptor expression contribute to α-MN defects in SMA patients? {#s3-4}
---------------------------------------------------------------------------------------------

m2R is expressed in α-MNs, with little to no expression in smaller gamma MNs ([@bib91]). This expression profile correlates with the pattern of neurodegeneration in an SMA mouse model: selective loss of α-MNs, while gamma MNs remain unaffected ([@bib70]). Within α-MNs, m2R is distributed along the membrane and concentrates at postsynaptic connections with C-boutons ([@bib13]). α-MNs in SMNΔ7 mice have increased C-bouton sites ([@bib83]), which could be an additional cause or consequence of increased m2R levels in α-MNs. Taken together, this evidence suggests that increased m2R is consistent with multiple features of SMA pathology. We also consider three additional previously defined m2R pathways as possible contributors to MN functional defects in SMN-deficient α-MNs: GIRK channels, Ca^2+^ channels, and SK channels.

Classically, m2R receptor activation leads to GIRK-channel-dependent efflux of K^+^ cations, resulting in neuronal hyperpolarization and decreased SV release ([@bib81]). Therefore, increased m2R levels are consistent with the synaptic defects observed in SMA models across species ([@bib17]; [@bib46]). m2R activation of GIRK channels is conserved in *C. elegans* ([@bib49]), suggesting GAR-2 loss may rescue NMJ defects in animals lacking SMN-1 by reducing GIRK channel activation. Interestingly, sustained GIRK activation has been previously linked to neurodegeneration ([@bib11]).

m2R inhibits N-type Ca^2+^ (Ca~v~2.2) and P/Q-type Ca^2+^ (Ca~v~2.1) channels resulting in decreased SV release at the NMJ ([@bib79]; [@bib95]). And, Ca~v~2.1-deficient mice exhibit NMJ degeneration and decreased active zone proteins ([@bib26]; [@bib64]). Additionally, in a mouse model of SMA, distal axons and growth cones had reduced Ca^2+^ transients resulting from defective Ca~v~2.2 excitability and accumulation ([@bib40]). Increased m2R is consistent with decreased Ca^2+^ channel activity observed in SMN-deficient animals. Moreover, Ca~v~2.2 channels activate SK channels in α-MNs, suggesting increased m2R may lead to decreased SK channel currents ([@bib29]). The drug riluzole, which ameliorated motor defects in *smn-1(ok355)* animals, may act *via* SK channels ([@bib16]). Increased m2R levels may result in excessive inhibition of SK channels, contributing to defective synaptic transmission in SMA models across species; this connection may offer additional mechanistic insight into the ameliorative effects of riluzole.

Previous reports suggest that decreases in Ca^2+^ transients hinder axon outgrowth ([@bib36]). SMN loss also decreases these currents ([@bib40]), consistent with defective axon outgrowth in SMN-deficient cultured neurons. Here, we show that inhibition of m2R by methoctramine ameliorates axon outgrowth defects in SMA mouse model MNs. As we find m2Rs are overexpressed in SMA MNs, methoctramine rescue of axon outgrowth may be the result of restored Ca^2+^ channel function. Taken together, these data suggest that increased m2R expression contributes to axon outgrowth defects in SMA MNs and that m2R inhibition promotes axon outgrowth in SMA MNs.

We connect SMN functionally and mechanistically to the miRNA pathway. As an exemplar of this connection in two species, we demonstrate that decreased SMN levels lead to downregulation of specific miRNAs and consequent increased expression of M2 muscarinic receptors. Increased m2R activity is deleterious and consistent with a subset of the NMJ defects seen in SMA models, across species. We suggest future studies might address the possible benefits of m2R inhibition in SMA models, as a combinatorial approach with other therapies.

Materials and methods {#s4}
=====================

*C. elegans* strains, constructs and transgenes {#s4-1}
-----------------------------------------------

Strains listed in [Supplementary file 2A](#SD17-data){ref-type="supplementary-material"} were maintained under standard conditions at 25°C ([@bib3]); we provide complete genotypes with unique strain identifiers, consistent with the rigorous standards of the *C. elegans* community. Abbreviated names are sometimes used for arrays, integrated lines or alleles in [Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}; additional information about abbreviations can be found in [Supplementary file 2C](#SD17-data){ref-type="supplementary-material"}. For experiments with *smn-1(ok355)* and *smn-1(rt248),* animals assayed were first generation progeny of hermaphrodites heterozygous for the *hT2* balancer. To maintain a common genetic background, control *smn-1(+)* animals were also derived from +/*hT2* parents. Similarly, for APT-4::GFP synaptic localization ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}) and aldicarb response studies ([Figure 6B](#fig6){ref-type="fig"}), *mel-46(tm1739)* animals were first generation progeny of parents heterozygous for the *nT1* balancer. Control *mel-46(+)* animals were derived from +/*nT1* animals. For all other assays involving *mel-46(tm1739)*, animals were first generation progeny of parents carrying the *ytEx211\[mel-46(+)\]* rescue array; animals tested did not carry the array unless specified. For these experiments, N2 animals served as wild type controls. We attempted to generate *smn-1(ok355);mel-46(tm1739)* double mutant animals, but generation of heterozygous double mutant animals was not possible, using either balancer chromosomes or the *ytEx211\[mel-46(+)\]* rescue array.

The pHA\#756 (*unc-17p::mir-2::unc-54* 3'UTR) plasmid was generated by excising a 867 bp fragment from pHA\#755 (*aex-3p::mir-2::unc-54* 3'UTR) using NheI and SpeI. This fragment, containing the genomic *mir-2* pre-miRNA sequence along with *unc-54* 3'UTR sequence, was subcloned into pPD95.77 (pPD95.77 was a gift from Andrew Fire; Addgene, Cambridge, Massachusetts plasmid 1495) between NheI and SpeI sites, resulting in removal of the GFP sequence. Additionally, a 4466 bp fragment corresponding to the *unc-17* promoter was inserted between pPD95.77 SphI and AscI sites. Information for all amplification primers can be found in [Supplementary file 2B](#SD17-data){ref-type="supplementary-material"}. pHA\#757 (*unc-17p::GFP::unc-54* 3'UTR) was generated by inserting the *unc-17* promoter fragment between pPD95.77 SphI and AscI sites, without altering the GFP sequence. Plasmid pHA\#758 (NLS::GFP::*gar-2* 3'UTRwt) contains a 269 bp fragment corresponding to the *gar-2* 3'UTR that was subcloned into pPD95.67 (pPD95.67 was a gift from Andrew Fire; Addgene plasmid 1490) as a EcoRI and SpeI product. pHA\#759 (*unc-17p::NLS::GFP::gar-2* 3'UTRwt) was generated by excising a 1286 bp fragment containing the NLS::GFP sequence and *gar-2* 3'UTR from pHA\#758 using MscI and SpeI and ligating this fragment into pHA\#756, thus removing the genomic *mir-2* pre-miRNA and *unc-54* 3'UTR sequences. pHA\#760 was generated by ligating the *gar-2* 3'UTR fragment into pBluescript KS+ (Stratagene, La Jolla, California) using EcoRI and SpeI. To construct pHA\#761, the last 85 bp of the *gar-2* 3'UTR were removed from pHA\#760 using NcoI and SpeI. This fragment was replaced with an identical 85 bp sequence, but with 19 bp scrambled at the predicted miR-2 binding site sequence (*gar-2* 3'UTRscr). Primers were annealed to produce this 85 bp sequence ([Supplementary file 2C](#SD17-data){ref-type="supplementary-material"}). Plasmid pHA\#762 (NLS::GFP::*gar-2* 3'UTRscr) was generated by subcloning the 269 bp *gar-2* 3'UTRscr fragment from pHA\#761 into pPD95.67 with EcoRI and SpeI. pHA\#763 (*unc-17p::NLS::GFP::gar-2* 3'UTRscr) was produced by subcloning the 1286 bp fragment containing NLS::GFP and *gar-2* 3'UTRscr sequences from pHA\#762 into pHA\#756 using MscI and SpeI, while removing the genomic *mir-2* pre-miRNA and *unc-54* 3'UTR sequences. pHA\#790 (*unc-122p::mel-46::unc-54* 3'UTR) was created by amplifying the MEL-46 coding region from the pRM8 plasmid ([@bib61]) and inserting this fragment into the pHA\#729 EcoRI site ([@bib17]). Using SphI and MscI restriction enzymes, the *unc-122* promoter was then excised and replaced with the 4466 bp *unc-17* promoter fragment excised from pHA\#763 with the same enzymes, thus generating pHA\#791 (*unc-17::mel-46::unc-54* 3'UTR). To create pHA\#792 (*unc-17p::mel-46*::GFP::*unc-54* 3'UTR), a 906 bp GFP sequence was amplified from pHA\#763 and subcloned by Gibson assembly into pHA\#791 just before the MEL-46 stop codon (TGA). The small guide RNA (sgRNA) plasmids targeting the *smn-1* gene (pHA\#764 and pHA\#765) and the sgRNA plasmid targeting the *gar-2* 3'UTR (pHA\#793) for CRISPR/Cas9-mediated genome editing were produced by amplification of *PU6::klp-12* ([@bib27]). Plasmid pHA\#766 contains a GFP insertion template and self-excising cassette flanked by *smn-1* arms of homology that were subcloned by Gibson assembly into pDD282 following a protocol from ([@bib14]).

Integrated arrays *rtIs64* and *rtIs65 \[unc-17p::mel-46*::GFP::*unc-54* 3'UTR\] were created by UV irradiation of *rtEx871*, which were generated by standard injection of pHA\#792 at 50 ng/μl, alongside 5 ng/μl *myo-3p::*mCherry (pCFJ104 - *myo-3p::*mCherry::*unc-54utr* was a gift from Erik Jorgensen ([@bib28]), and 75 ng/μl pBluescript KS+. To generate *rtEx855\[*pRM8(*mel-46(*+); *myo-2p*::RFP\], wild type animals were injected with 133 ng/μl PRM8 plasmid ([@bib61]), 5 ng/μl *myo-3p::*mCherry; Addgene plasmid 19328) and 75 ng/μl pBluescript KS+. Animals injected with rtEx855\[pRM8(*mel-46(+); myo-3p-*RFP)\] were crossed into a *mel-46(tm1739)* background to assure rescue of viability before further experiments were undertaken. Notably, expression of either *rtEx855* or *ytEx211* in *smn-1(lf)* animals did not rescue lethality or adult survival, further emphasizing a privileged relationship between SMN-1 and MEL-46 in cholinergic NMJ signaling. Lines for *rtEx853\[unc-17p::mir-2; myo-2p::mCherry\]* and *rtEx854\[unc-17p::GFP; myo-2p::mCherry\]* were produced by injecting *mir-2(gk259)* animals with pHA\#756 or pHA\#757, respectively, a*t 40* ng/μl alongside 2.5 ng/μl *myo-2p::*mCherry (pCFJ90 - *myo-2p::*mCherry*::unc-54utr* was a gift from Erik Jorgensen ([@bib28]); Addgene plasmid 19327) and 77.5 ng/μl pBluescript KS+. *rtIs56\[unc-17p::GFP::gar-2 3'UTRwt; myo-2p::mCherry\]* was integrated by UV irradiation into the genome and is derived from extrachromosomal array *rtEx856*, containing pHA\#759, which was injected into wild type animals at 20 ng/μl with 2.5 ng/μl *myo-2p::mCherry* and 77.5 ng/μl pBluescript KS+. Integrated arrays *rtIs57* and *rtIs58 \[unc-17p::GFP::gar-2 3'UTRscr; myo-2p::mCherry\]* are two separate lines generated by UV irradiation of extrachromosomal array *rtEx857,* containing pHA\#763, which was injected into wild type animals at 20 ng/μl with 2.5 ng/μl *myo-2p::mCherry* and 77.5 ng/μl pBluescript KS+. *gar-2(rt317)* and *gar-2(rt318)* alleles were generated by injecting *pha-1*(*e2123*) animals with the pHA\#793 sgRNA plasmid targeting the *gar-2* 3'UTR at 25 ng/μl with either 50 ng/μl of a mutant single-strand oligo DNA (ssODN) repair template (*rt318)* or a control ssODN repair template (*rt317*), alongside the injection cocktail as described in [@bib90]. Progeny from this injection were screened as described ([@bib90]). Information on ssODN template sequences can be found in [Supplementary file 2C](#SD17-data){ref-type="supplementary-material"}. To generate *smn-1(rt280),* which contains a GFP N-terminal insertion, wild type animals were injected with both pHA\#764 and pHA\#765 sgRNA plasmids targeting *smn-1* at 50 ng/μl alongside 20 ng/μl of the GFP template plasmid pHA\#766 and the standard injection cocktail described in [@bib14]. Progeny from this injection were screened as described ([@bib14]). Consistent with Miguel-Aliaga et al., we noticed that the tagged-SMN protein was expressed in all blastomeres throughout embryonic development with redistribution from the nucleus to the cytoplasm during mitotic stages (data not shown). The presence of GFP::SMN during such early stages indicates that GFP::SMN is maternally transmitted during germline development ([@bib60]).

RNAi studies {#s4-2}
------------

RNAi studies involved animals from an RNAi-enhanced background (KP3948) ([@bib44]), neuron-specific RNAi-sensitized background (TU3401) ([@bib5]), cholinergic neuron-specific RNAi-sensitized background (XE1581), or GABA neuron-specific RNAi-sensitized background (XE1375) ([@bib25]). Aldicarb response, pumping rates, and RNA quantification were evaluated in animals that had been reared for at least two generations on HT115 bacteria containing control vector L4440, C41G7.1/*smn-1(RNAi),* C26C6.2/*goa-1(RNAi)*, T06A10.1/*mel-46(RNAi),* or Y37D8A.23/*unc-25(RNAi)* ([@bib42]). Primer sequences used to generate the PCR products specific to each gene of interest can be found on the Kim Lab Stanford University website (<http://cmgm.stanford.edu/~kimlab/primers.12-22-99.html>).

*C. elegans* behavioral assays {#s4-3}
------------------------------

*Aldicarb resistance assay:* 1 mM aldicarb assays were completed in at least three independent trials blinded to genotype (n ≥ 30 animals/genotype) as described in previous work ([@bib54]; [@bib74]). Paralysis induced by aldicarb was scored as inability to move or pump in response to prodding with a platinum wire. Experiments involving *smn-1(ok355), smn-1(rt248)* or *mel-46(tm1739)* animals were completed at the early L4 stage. All other aldicarb experiments were done with young adult animals. *Pharyngeal pumping:* Assays were performed blinded to genotype as previously described ([@bib15]). Pumping events were scored as grinder movement in any axis. Average pumping rates (± Standard Error of the Mean (SEM)) were pooled from at least two independent trials (n \> 20 animals/genotype). Experiments involving *smn-1(ok355), smn-1(rt248)* or *mel-46(tm1739)* animals were completed at day three post-hatching (animals were kept at 25**°**C for two days and then 20**°**C for one day). Pumping experiments involving all other genotypes were done with young adult animals.

*C. elegans* light level microscopy {#s4-4}
-----------------------------------

Animals were mounted on 2% agar pads and immobilized using 30 mg/mL BDM (Sigma) in M9 buffer. *Dorsal cord protein localization:* Images were obtained as Z-stacks of the dorsal cord above the posterior gonad reflex (100x objective, Zeiss (Jena, Germany) AxioImager ApoTome and Axiovision software v4.8). For MEL-46::GFP analysis, a set area was defined for each image along the dorsal cord (25 µm x 5 µm). Using ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)), a uniform threshold was used to eliminate background. The number (density), mean fluorescence (intensity) and area (size) for MEL-46::GFP granular structures were calculated using the ImageJ 'particle analyzer' program. For synaptic protein localization, mean puncta width (meanfixedwidth), intensity (meanfixedvolume) and linear density (fixedwidthlineardensity) were quantified with an in-house developed program called 'Punctaanalyser' using MatLab software (v6.5; Mathworks, Inc., Natick, MA, USA; RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)) ([@bib45]). At least three independent trials (n \> 17 animals/genotype) were performed. For data sets involving *smn-1(ok355), smn-1(rt248),* or *mel-46(tm1739)* animals, all genotypes were examined at the early L4 stage, while other data sets were collected with young adult stage animals. *GFP Fluorescence Quantification:* GFP images of L4 animals were acquired (10x objective, Zeiss V20 stereoscope and Axiovision software v4.8). Mean GFP fluorescence was quantified using ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)). A threshold was set to eliminate background fluorescence. For each data set, thresholds were kept constant. Average fluorescence values (±SEM) were combined from at least three independent trials for n \> 25 animals/genotype; however certain backgrounds containing *rtEx855\[mel-46(+)\]* had a lower n (reported in legends) as these animals went sterile and/or did not throw many progeny carrying the *mel-46* array. Ratios in [Figure 4H](#fig4){ref-type="fig"} and [Figure 5A](#fig5){ref-type="fig"} were calculated as average mean fluorescence for each genotype in the *rtIs56* background and divided by their respective average mean fluorescence in the control *rtIs57* background. Ratio SEM was calculated by summing the SEM for each population (see [Figure 4---figure supplement 2D](#fig4s2){ref-type="fig"}). All representative images shown were analyzed as part of data collection.

*C. elegans* total RNA isolation, cDNA synthesis and qPCR {#s4-5}
---------------------------------------------------------

For each RNA sample, animals were synchronized by collecting eggs for 6 hr from gravid adults on large seeded NGM plates. After two days at 25°C, young adult progeny were washed off, rinsed and flash frozen. Total RNA was extracted after a 15 min Trizol (Thermo Fisher, Waltham, Massachusetts) incubation. 1 ng total RNA was used for reverse transcription with either the miScript II RT kit (Qiagen \#218160) for miRNA or the SuperScript III First-Strand Synthesis Supermix kit (Invitrogen \#11752050) for mRNA. Methodology followed manufacturer's instructions. miRNA levels were determined in a 10 µl reaction using miScript SYBR Green PCR kit (\#218073, Qiagen, Venlo, Netherlands) and 300 nM of mature miR-2 primer/probe. miR-60 was used to normalize miR-2 expression as it is not expressed in the nervous system where SMN-1 or MEL-46 were knocked-down. Forward primer sequences for miR-2 and miR-60 were, respectively: 5'-TATCACAGCCAGCTTTGATGTGC-3' and 5'-TATTTATGCACATTTTCTAGTTCA-3'. A universal reverse probe was provided by Qiagen. Primer sequences for *act-1*: 5'-acgccaacactgttctttcc-3' and 5'-gatgatcttgatcttcatggttga-3' ([@bib53]). Primer sequences for 18S rRNA: 5'-TTGCTGCGGTTAAAAAGCTC'3' and 5'-CCAACCTCAAACCAGCAAAT-3' ([@bib22]). The stability of miR-60, 18S rRNA, and *act-1* housekeeping RNAs were evaluated using the 'model-based approach to estimation of expression variation' ([@bib2]). mRNA levels were determined in a 10 µl reaction using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific \# 4368706), and 300 nM of each primer. PGK-1 was used to normalize *gar-2* expression, as the mammalian orthologue has been used previously as a housekeeping gene for experiments involving SMN ([@bib1]; [@bib77]). Primer sequences for *gar-2*: 5'-CCTGAACTCTCATTGCCCTTTATTGATGC-3' and 5'-CTAGCAGTCCCTTGCATTGAAAC-3'. Primer sequences for *pgk-1*: 5'-GGCCCTCGACAACCCAGCTCGTC-3' and 5'-CGGCGGAGGAATGGCCTATACC-3. All reactions were performed in triplicate. Melting curve analysis and electrophoresis in agarose gel of every PCR product was conducted after each qRT-PCR to control amplification specificity. Gene expression level was calculated as the fold change of relative DNA amount of a target gene in a target sample and a reference sample normalized to a reference gene using the comparative ΔΔCT method as previously described ([@bib47]).

Embryonic spinal MN culture, miR-128a quantification and Western blot {#s4-6}
---------------------------------------------------------------------

E13.5 mouse MNs were isolated from WT (FVB/NJ; RRID:[IMSR_JAX:001800](https://scicrunch.org/resolver/IMSR_JAX:001800)) and SMA mice (FVB, *Smn*^-/-^;*SMN2*^tg/0^; generated by crossing lines RRID:[IMSR_JAX:005058](https://scicrunch.org/resolver/IMSR_JAX:005058) and RRID:[IMSR_JAX:005024](https://scicrunch.org/resolver/IMSR_JAX:005024)) ([@bib72]) as described ([@bib94]). Isolated mouse MNs were differentiated 10 days in NB/B27 media supplemented with growth factors to promote survival; brain derived neurotrophic factor (BDNF) 10 ng/ml, ciliary neurotrophic factor (CNTF) 10 ng/ml and glial-derived neurotrophic factor (GDNF) 50 ng/ml. Fifty percent of medium was replaced every three days. To reduce the amount of glia and fibroblasts in culture, 1 µM cytosine arabinoside (AraC) was added at day 3.

After 10 days in vitro culture, total RNA was extracted from MNs using the mirVana total RNA isolation kit (Thermo Scientific). Nanodrop was used to measure RNA amount. Using 100 ng of total RNA, miR-128 expression levels were determined by real time PCR with mature miR-128a primer/probe (TaqMan MicroRNA Assays, \#4427975, Thermo Scientific). Actin-beta was used to normalize miR-128a expression. Primer sequences for actin-beta: 5\'-agccatgtacgtagccatcc-3\' and reverse 5\'-ctctcagctgtggtggtgaa-3\'. Methodology followed manufacturer's instruction ([@bib48]).

Proteins were extracted from motor neurons, after 10 days in vitro culture, using RIPA buffer and protease inhibitor cocktail ([@bib80]). Expression of m2R and β-actin was measured using Western blot. Antibodies against m2R (ABCAM, ab109226; RRID:[AB_10858602](https://scicrunch.org/resolver/AB_10858602); 1:1000) and β-actin (Santa Cruz, sc-47778; RRID:[AB_626632](https://scicrunch.org/resolver/AB_626632); 1:1000) were used to detect proteins. Methoctramine (Sigma, M105) was treated 48 hr from DIV3 to DIV5 in various concentrations. After 5 days of in vitro culture, neuronal morphology was visualized with Tau (Santa Cruz, A-10) staining. Axon length was analyzed with ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)).

Statistical analysis {#s4-7}
--------------------

Log-rank test, two-tailed Mann-Whitney *U*-test, or *t-*test were used for *C. elegans* statistical analysis. The Mann Whitney *U*-test was chosen over *t-*test for experiments where homogeneity could not be assured (i.e. RNAi; extrachromosomal arrays; or potential maternal loading from a heterozygous parent). *t*-test was used to determine significance for spinal motor neuron Western blot quantification and qPCR quantification.
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###### Summary of *C. elegans* experiments.

\(A\) Summary of synaptic protein localization experiments; percent change from control for all metrics. (B) Summary of *C. elegans* phenotypes for selected loss of function alleles from this study as well as those identified in previous literature. *Related to [Figures 1](#fig1){ref-type="fig"}--[6](#fig6){ref-type="fig"} and their figure supplements.*
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###### *C. elegans* strains and other materials utilized.

\(A\) Strains used for this work; related to materials and methods. (B) Primers and ssODNs used for this work; related to materials and methods. (C) Arrays/integrated lines/alleles with abbreviation in text and figures. 
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Decision letter

Hobert

Oliver

Reviewing editor

Howard Hughes Medical Institute, Columbia University

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Decreased SMN causes deleterious increases in neuronal M2 muscarinic receptors due to microRNA misregulation\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The authors harness the power of C.elegans genetics to interrogate the defects incurred by loss of SMN on neuromuscular function. Using a series of approaches, the authors implicate the worm ortholog of Gemin3 (*mel-46*), the miR-2 and the M2 muscarinic receptor. The study demonstrates the power of a genetically tractable system to understand fundamental biology. Based on their data and previously published work, the authors propose the following:

1\) SMN-1 acts genetically through MEL-46/Gemin3. Molecularly, SMN-1 is necessary to achieve normal levels of MEL-46/Gemin3.

2\) Normal levels of Gemin3 are necessary for correct miRNA processing/function, including *mir-2.*

3\) *mir-2* is necessary to repress *gar-2*. GAR-2 is an M2 receptor that is predicted to inhibit synaptic release at cholinergic NMJs and thus needs to be kept at relatively low levels for optimal NMJ function

These conclusions are based on a number of relatively indirect measures, which are for the most part not sufficient to support all claims. In essence, a number of qPCR experiments are required to support a number of conclusions. Specifically:

1\) The authors propose that reduction of SMN-1 results in lower levels of MEL-46. This is based on one genetic interaction: the fact that *mel-46* overexpression rescues part of the defects observed in *smn-1(lf)* animals, most prominently, it suppresses the aldicarb resistance of *smn-1(lf)* animals. However, it does not rescue the pharyngeal defect of *smn-1(lf)*, suggesting some kind of tissue specificity. Since the connection to miRNA processing/function is given by MEL-46/Gemin3, I think it\'s important to provide a more direct link and the authors need to measure *mel-46* (RNA using qPCR and/or protein) in *smn-1(lf)*.

This is important given that an alternative explanation is not satisfactorily rejected. Specifically, the authors discard an effect of MEL-46 in stabilizing the maternal contribution of SMN-1 by quantifying GFP fluorescence from a very nice SMN-1::GFP allele generated with Cas9, over whole worms, in wt animals with or without MEL-46 overexpression. However, given that in all phenotypic assays the effect of MEL-46 is only seen in the *smn-1(lf)* background but not in the wt background, it is not clear if one would expect to see any changes in SMN-1 abundance in wt animals. A more direct test would have been to look at the remaining GFP in the *smn-1(lf)* progeny from heterozygous mothers and see whether this changes with overexpression of MEL-46. Also, given the tissue specificity observed phenotypically, it may be more revealing to focus e.g. on motorneurons. Although if levels are too low to see GFP, a western blot against GFP may already provide some information.

2\) The connection of SMN to miRNAs through Gemin3 is solely based on previous publications reporting the dysregulation of certain miRNAs when SMN or Gemin3 are decreased. There is no direct connection in this work between this pathway and *mir-2*, the miRNA the authors find to be important for NMJ function. Based on the data provided, *mir-2* could be acting in the NMJs in a parallel pathway that has no connection to SMN-1 or MEL-46. To strengthen this link, the authors need to measure *mir-2* levels in *smn-1(lf), mel-46* mutants or overexpression strains. However, one has to wonder whether there is a connection at all: The authors claim to provide a link (although very indirect) with an epistasis analysis shown in [Figure 4](#fig4){ref-type="fig"} where they look at a fluorescent reporter for *gar-2*, the predicted target of *mir-2*. The authors compare a reporter with the wt 3\'UTR and one without the mir-2 binding site in wt animals or *smn-1(lf)*. In wt animals, the fluorescence ratio between the two reporters is \~1 and in *smn-1(lf)* animals it goes up by 5% (to 1.05). The authors suggest this is consistent with *mir-2* levels being lower in *smn-1(lf)* (because of lower mel-46/Gemin3, which is not shown) and that leads to *gar-2* derepression. In addition to this being an extremely small effect that would need additional data to be convincing (e.g. qPCR of *gar-2* mRNA in N2 v miR-2 mutant animals), there is a problem which is that the increase in ratio is not as one would expect from the reporter with the wt 3\'UTR being derepressed (numerator going up) in *smn-1(lf)* but rather the reporter with the mutant 3\'UTR is decreased in *smn-1(lf)* (denominator going down) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panels C and D). There is no other connection provided between the effect that *smn-1* and *mel-46* may have on the NMJ and whatever function *mir-2* might have there as well.

3\) The phenotypic and reporter analyses are consistent with *gar-2* being a target of *mir-2*. Given the small magnitude of repression observed, this point could be made more convincingly, for example by mutating the *mir-2* binding site in the 3\'UTR of *gar-2*, which should not be too difficult given that the authors are able to generate alleles using Cas9.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Decreased microRNA levels lead to deleterious increases in neuronal M2 muscarinic receptors in Spinal Muscular Atrophy models\" for further consideration at *eLife*. Your revised article has been favorably evaluated by a Senior Editor, a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have done a highly appreciated effort to incorporate the reviewers' comments and suggestions and I think this has paid off in strengthening their model. However, one concern remains about a critical link in the story: The changes in *mir2* measurements ([Figure 5](#fig5){ref-type="fig"}), an important and good addition, needs to be done with better controls. Currently, the authors report *mir-2* levels relative to *mir-60* levels. This is another miRNA that might also be affected by the manipulations done in this experiment. It is not clear at all from looking at the raw data provided whether in these experiments *mir-2* is decreasing or *mir-60* is increasing, in fact the latter seems more supported by the data. There is also a problem of reproducibility in this experiment, with variances of \>10 Ct between replicates. It is strongly suggested that given the importance of this experiment, it should be repeated with additional normalization controls, which should include at least one non-miRNA RNA (U6, U18, 5S RNA). One suggestion for improving reproducibility is to use a remarkably well-working protocol published by Kien Ly, Suzanne J. Reid, Russell G. Snell as \"Rapid RNA analysis of individual *Caenorhabditis elegans*\" in MethodsX 2 (2015) 59-63.
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Author response

*\[...\] These conclusions are based on a number of relatively indirect measures, which are for the most part not sufficient to support all claims. In essence, a number of qPCR experiments are required to support a number of conclusions. Specifically:*

*1) The authors propose that reduction of SMN-1 results in lower levels of MEL-46. This is based on one genetic interaction: the fact that mel-46 overexpression rescues part of the defects observed in smn-1(lf) animals, most prominently, it suppresses the aldicarb resistance of smn-1(lf) animals. However, it does not rescue the pharyngeal defect of smn-1(lf), suggesting some kind of tissue specificity. Since the connection to miRNA processing/function is given by MEL-46/Gemin3, I think it\'s important to provide a more direct link and the authors need to measure mel-46 (RNA using qPCR and/or protein) in smn-1(lf).*

*This is important given that an alternative explanation is not satisfactorily rejected. Specifically, the authors discard an effect of MEL-46 in stabilizing the maternal contribution of SMN-1 by quantifying GFP fluorescence from a very nice SMN-1::GFP allele generated with Cas9, over whole worms, in wt animals with or without MEL-46 overexpression. However, given that in all phenotypic assays the effect of MEL-46 is only seen in the smn-1(lf) background but not in the wt background, it is not clear if one would expect to see any changes in SMN-1 abundance in wt animals. A more direct test would have been to look at the remaining GFP in the smn-1(lf) progeny from heterozygous mothers and see whether this changes with overexpression of MEL-46. Also, given the tissue specificity observed phenotypically, it may be more revealing to focus e.g. on motorneurons. Although if levels are too low to see GFP, a western blot against GFP may already provide some information.*

We appreciate the reviewer's criticism and the opportunity to show a more direct connection between SMN-1 and MEL-46. To confirm that loss of SMN-1 affects the function and/or levels of MEL-46, we have now generated two independent integrated lines expressing MEL-46 tagged with GFP behind the control of the cholinergic-specific *unc-17* promoter ([Figure 2A](#fig2){ref-type="fig"}). Using these, we were able to evaluate the effects of SMN-1 loss on MEL-46 levels and localization in cholinergic neurons. This seemed the most specific approach to quantify the effect of SMN-1 loss on MEL-46 in motor neurons. After crossing both independent integrated lines into the *smn-1(ok355*) background, we found an obvious defect in MEL-46 localization in dorsal cord motor neurons processes. We find that MEL-46::GFP in wild type control animals is sparsely localized to punctate structures along the dorsal cord (see [Figure 2C](#fig2){ref-type="fig"}). These structures are likely similar to axonal granules containing MEL-46, which have been reported in mammalian tissue culture studies (Todd et al., 2010a; Todd et al., 2010b; Zhang et al., 2006). In *smn-1(ok355*) animals, MEL-46::GFP is found in many more granules, with an average decrease in MEL-46::GFP fluorescence within granules ([Figures 2B](#fig2){ref-type="fig"}-[1D](#fig1){ref-type="fig"}). MEL-46::GFP mislocalization and decreased intra-granule levels in *smn-1(ok355)* cholinergic neurons support our model in which MEL-46 function is perturbed when SMN-1 levels decrease.

Unfortunately, we were unable to directly evaluate levels of maternally-loaded SMN-1::GFP in *smn-1(ok355)* homozygous animals. The simplest strategy would be to tag the endogenous *smn-1* gene on the balancer chromosome used to propagate *smn-1(ok355).* Using the CRISPR-based approach outlined in the manuscript and suggested by the reviewer, we attempted to GFP-tag endogenous *smn-1* on balancer chromosomes *hT2* and *ccIs425*. We were unsuccessful after multiple attempts. Therefore, we cannot unequivocally conclude that increased MEL-46 does not lead to increased stabilized maternally-loaded SMN-1. We make this caveat clear in the revised text (see "changes made to text" below). Given the severe MEL-46 localization defects we observe in *smn-1(ok355)* animals, however, it is more likely that increased MEL-46 proteins levels ameliorate *smn-1(ok355)* defectsby increasing MEL-46 within critical granules in motor neurons, like those in the dorsal cord. See [Figures 2A-D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}.

Changes made to text for Editor Point 1:

"MEL-46 might act together with or downstream of SMN-1 in pathways necessary for NMJ function. \[...\] Our findings suggest that SMN-1 impairs MEL-46 function, which could contribute *to smn-1(ok355)* synaptic defects (Dimitriadi et al., 2016)."

"Using the same CRISPR-based method, we were unable to tag endogenous *smn-1* on balancer chromosomes necessary for maintaining the *smn-1(ok355)* line. \[...\] Therefore, although we cannot rule out stability of maternally-loaded SMN-1 as a contributing factor, the large effect that decreased SMN-1 has on MEL-46 localization favors a mechanism in which MEL-46 overexpression rescues *smn-1(ok355)* defects, at least in part, by restoring MEL-46 functional deficits in this background."

*2) The connection of SMN to miRNAs through Gemin3 is solely based on previous publications reporting the dysregulation of certain miRNAs when SMN or Gemin3 are decreased. There is no direct connection in this work between this pathway and mir-2, the miRNA the authors find to be important for NMJ function. Based on the data provided, mir-2 could be acting in the NMJs in a parallel pathway that has no connection to SMN-1 or MEL-46. To strengthen this link, the authors need to measure mir-2 levels in smn-1(lf), mel-46 mutants or overexpression strains. However, one has to wonder whether there is a connection at all: The authors claim to provide a link (although very indirect) with an epistasis analysis shown in [Figure 4](#fig4){ref-type="fig"} where they look at a fluorescent reporter for gar-2, the predicted target of mir-2. The authors compare a reporter with the wt 3\'UTR and one without the mir-2 binding site in wt animals or smn-1(lf). In wt animals, the fluorescence ratio between the two reporters is \~1 and in smn-1(lf) animals it goes up by 5% (to 1.05). The authors suggest this is consistent with mir-2 levels being lower in smn-1(lf) (because of lower mel-46/Gemin3, which is not shown) and that leads to gar-2 derepression. In addition to this being an extremely small effect that would need additional data to be convincing (e.g. qPCR of gar-2 mRNA in N2 v miR-2 mutant animals), there is a problem which is that the increase in ratio is not as one would expect from the reporter with the wt 3\'UTR being derepressed (numerator going up) in smn-1(lf) but rather the reporter with the mutant 3\'UTR is decreased in smn-1(lf) (denominator going down) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, panels C and D). There is no other connection provided between the effect that smn-1 and mel-46 may have on the NMJ and whatever function mir-2 might have there as well.*

We thank the reviewers for these suggestions. The work we have consequently done with qPCR analysis of miR-2 and *gar-2* transcripts greatly strengthens the manuscript. We focused specifically on how decreasing SMN-1 or MEL-46 within neurons impacts mature miR-2 levels and *gar-2* mRNA levels. To do this, we undertook RNAi studies using animals sensitive to RNAi by feeding only in neurons (Calixto et al., 2010). These animals were placed on bacteria expressing SMN-1 or MEL-46 RNAi constructs for at least two generations. We found that knock-down of either SMN-1 or MEL-46 resulted in a large (\~80%) decrease in miR-2 levels. These results are consistent not only with a role for both SMN-1 and MEL-46 in miR-2 biogenesis, but further suggest a relationship between SMN-1 and MEL-46 in a pathway important for proper miRNA function. In measuring *gar-2* transcript from these samples, we found that this decrease in miR-2 levels did not result in significantly increased *gar-2* mRNA levels. This was unsurprising as *gar-2* mRNA levels were also not significantly increased in *mir-2(gk259)* loss of function animals compared to N2 control animals ([Figure 4I](#fig4){ref-type="fig"}). Previous reports have found that changes in miRNA levels do not necessarily result in changes in target transcript levels. Instead, miRNAs may bind their targets and inhibit translation without transcript destabilization (Cloonan, 2015; Selbach et al., 2008). Overall, these data support our model and further suggest that SMN-1 and MEL-46 not only impact miRNA activity, but may play a role in miRNA biogenesis.

See [Figure 4I](#fig4){ref-type="fig"} and [Figures 5B-C](#fig5){ref-type="fig"}.

Changes made to text for Editor Point 2:

"We also assessed the effect of miR-2 loss on *gar-2* transcript levels and found no significant difference in *gar-2* mRNA levels between wild type animals and *mir-2(gk259)* loss of function animals ([Figure 4I](#fig4){ref-type="fig"}). \[...\] Previous studies have reported that miRNAs can influence protein synthesis of targets without destabilizing mRNA levels (Cloonan, 2015; Selbach et al., 2008)."

"Increased GAR-2 translation in animals lacking SMN-1 might be due to decreased mature miR-2 levels. \[...\] These results suggest neuronal miR-2 levels are decreased when MEL-46 or SMN-1 levels decrease."

3\) The phenotypic and reporter analyses are consistent with gar-2 being a target of mir-2. Given the small magnitude of repression observed, this point could be made more convincingly, for example by mutating the mir-2 binding site in the 3\'UTR of gar-2, which should not be too difficult given that the authors are able to generate alleles using Cas9.

We agree. CRIPSR/Cas-9-based genome editing was used to scramble the microRNA binding site in the *gar-2* 3'UTR. Animals with a scrambled endogenous miR-2 binding site in the *gar-2* 3'UTR were resistant to aldicarb, when compared to control animals ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, animals with the scrambled binding site in the *gar-2* 3'UTR had increased levels of *gar-2* messenger RNA ([Figure 4D](#fig4){ref-type="fig"}). These results strengthen the model in which *gar-2* is a direct target of miR-2. This result is perplexing, however, since *mir-2(gk259)* animals did not have significantly increased *gar-2* transcript levels. We note that other miR-2 family members likely bind this site, including miR-43, miR-250, and miR-797. Additionally, our qPCR results come from whole animal lysate. Thus, the increase in *gar-2* messenger RNA likely results from the inability of all miR-2 family members to bind the *gar-2* 3'UTR throughout all tissues. These family members may act differently than miR-2, resulting in transcript destabilization when bound. Furthermore, since miR-2 appears to be limited to the nervous system, the effect it has on *gar-2* transcript in neurons may be minimized by levels of the more broadly-expressed *gar-2* transcript. This may explain why a significant difference in transcript levels is seen when the binding site is scrambled, but not in *mir-2(gk259)* loss of function animals.

See [Figure 4B-C](#fig4){ref-type="fig"} and [Figure 4H](#fig4){ref-type="fig"}.

Changes made to text for Editor Point 3:

"To determine if miR-2 regulates GAR-2 expression directly, we examined the consequences of perturbing the putative miR-2 binding site in the *gar-2* 3'UTR. \[...\] Disruption of the 3'UTR site likely inhibits binding of other miR-2 family members, likely contributing to the effect we observe (Ibanez-Ventoso et al., 2008)."

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*The authors have done a highly appreciated effort to incorporate the reviewers' comments and suggestions and I think this has paid off in strengthening their model. However, one concern remains about a critical link in the story: The changes in mir2 measurements ([Figure 5](#fig5){ref-type="fig"}), an important and good addition, needs to be done with better controls. Currently, the authors report mir-2 levels relative to mir-60 levels. This is another miRNA that might also be affected by the manipulations done in this experiment. It is not clear at all from looking at the raw data provided whether in these experiments mir-2 is decreasing or mir-60 is increasing, in fact the latter seems more supported by the data. There is also a problem of reproducibility in this experiment, with variances of \>10 Ct between replicates. It is strongly suggested that given the importance of this experiment, it should be repeated with additional normalization controls, which should include at least one non-miRNA RNA (U6, U18, 5S RNA). One suggestion for improving reproducibility is to use a remarkably well-working protocol published by Kien Ly, Suzanne J. Reid, Russell G. Snell as \"Rapid RNA analysis of individual Caenorhabditis elegans\" in MethodsX 2 (2015) 59-63.*

We thank the reviewer for these suggestions. We undertook the additional experiments suggested by the reviewer. We increased the number of samples from 3 to 6 for each group and examined miR-2 expression levels relative to 3 different RNAs: a microRNA (miR-60), a ribosomal RNA (18S), and a messenger RNA *(act-1).* After either *mel-46* and *smn-1* RNAi treatments, we observed decreased miR-2 levels, normalized to any of these 3 RNAs relative to empty RNAi ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}). In the revised manuscript, we report miR-2 levels relative to miR-60 levels in the main figures and include miR-2 levels relative to *act-1* and 18S rRNA in the supplementary figures (Martinez et al., 2008). We utilized previously reported amplification primers for both 18S rRNA (Essers et al., 2015) and *act-1* (Ly et al., 2015). This extended analysis makes clear that miR-2 levels decrease when *smn-1* or *mel-46* function decreases.

Choosing an appropriate control RNA can be challenging; here we examined 3 different possibilities. We evaluated the stability of each of the putative "control RNAs" under the different experimental conditions using the "model-based approach to estimation of expression variation" (Andersen et al., 2004). This mathematical model is used to describe the "stability value" of candidate genes- taking in account variability within a group of samples under the same treatment conditions and between groups of samples under different treatment conditions. Lower "stability values" for a given group of genes indicate more stable expression. We find that miR-60 is the most stable RNA (stability value = 0.250), compared to 18S rRNA or *act-1* (0.316 and 0.376, respectively). As miR-60 is the most stable candidate, we use it as a control in the main text figures.

See [Figures 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}.

Changes made to text for Editor Point 1:

"After neuron-specific RNAi knock-down of either SMN-1 or MEL-46, we found decreases in mature miR-2 levels ([Figure 5B](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}), but no change in *gar-2* transcript levels ([Figure 5C](#fig5){ref-type="fig"})."

"Primer sequences for *act-1*: 5'-acgccaacactgttctttcc-3' and 5'-gatgatcttgatcttcatggttga-3' (Ly et al., 2015). Primer sequences for 18S rRNA: 5'-TTGCTGCGGTTAAAAAGCTC'3' and 5'-CCAACCTCAAACCAGCAAAT-3' (Essers et al., 2015). The stability of miR-60, 18S rRNA, and *act-1* housekeeping RNAswere evaluated using the 'model-based approach to estimation of expression variation' (Andersen et al., 2004)."

"miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty*(RNAi), smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping miRNA miR-60. *t-*test, two-tailed (n=6 for each condition)."

"(C) miR-2 levels were decreased in neurons when either SMN-1 or MEL-46 were decreased. Quantification of mature miR-2 for empty*(RNAi), smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping gene *act-1*. \[...\] Quantification of mature miR-2 for empty*(RNAi), smn-1(RNAi)*, and *mel-46(RNAi)* young adult animals relative to housekeeping rRNA 18s. *t-*test, two-tailed (n=6 for each condition)."
